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ABSTRACT 
Enterococcal endocarditis accounts for an increasing proportion 
(about 10-15%) of cases of endocarditis in recent years. The combina¬ 
tion of a penicillin and an aminoglycoside has become an accepted 
standard of treatment for this disease. However, the optimal choice of 
antibiotics, the duration of therapy, and the timinq of surgical inter¬ 
vention remain controversial issues. 
This study reviews the presentations, clinical courses, treat¬ 
ments, and outcomes of 37 patients with 42 separate episodes of entero¬ 
coccal endocarditis at four Yale University hospitals. Certain clinical 
features (age over 60 years, female sex, congestive heart failure, 
prosthetic valve infection, relapsing endocarditis, and a vegetation 
on ultrasound) correlated with a poor prognosis. A longer duration of 
illness prior to diagnosis was associated with a higher incidence of 
some but not all complications. 
Patients who received valve replacements during or after antibiotic 
therapy had a higher treatment success rate than those treated with 
antibiotics alone. In addition, patients treated with an aminoglycoside 
and a penicillin or vancomycin had significantly better outcomes than 
those whose regimens did not include an aminoglycoside. However, the 
duration of aminoglycoside therapy (greater than 4 weeks versus less 
than 4 weeks) did not appear to have a significant effect on outcome. 
These results suggest that excellent cure rates may be achieved after 
treatment with less than 4 weeks of an aminoglycoside in combination 
with a penicillin or vancomycin, thus potentially avoiding significant 
renal and vestibular toxicity. Further clinical investigation is 
warranted to determine the minimum length of aminoglycoside therapy 
associated with optimal outcome in enterococcal endocarditis. 
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INTRODUCTION 
The prognosis for patients with infective endocar¬ 
ditis (IE) has improved significantly over recent de¬ 
cades, yet endocarditis continues to present unique diag¬ 
nostic, prognostic, and therapeutic dilemmas for the 
clinician. Review of the changing microbiologic spectrum 
of the disease clearly demonstrates an increasing propor¬ 
tion of cases caused by enterococci, despite a decline in 
the fraction of endocarditis cases attributable to strep¬ 
tococci as a whole. 
The enterococcus must be distinguished from other 
streptococci, in particular from other group D strepto¬ 
cocci, through a series of microbiologic tests because 
the recommended treatments of enterococcal and non- 
enterococcal group D streptococcal endocarditis are very 
different. Relative to other streptococci, the entero¬ 
coccus is more resistant to penicillin and is an unusual¬ 
ly virulent organism. These features may be responsible 
for the apparent poorer prognosis associated with this 
type of endocarditis as compared with viridans and .£. 
bovis endocardial infections. 
Furthermore, the most effective and least toxic an- 
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tibiotic therapy for enterococcal endocarditis (EE) has 
not been definitively determined and remains controver¬ 
sial. Four to six weeks of combination therapy are most 
often used in an attempt to achieve cure. The recommend¬ 
ed regimen includes a cell wall active agent (penicillin, 
ampicillin, or vancomycin) in combination with an amino¬ 
glycoside. In addition, the treatment for this disease 
in patients with serious penicillin hypersensitivity has 
not yet been standardized. 
There have been no controlled prospective studies 
investigating the optimal therapy for EE. This can be 
attributed to the relatively small numbers of patients 
with this diagnosis in any given hospital. Clinical de¬ 
cisions have, therefore, been based on retrospective ana¬ 
lyses of cases. 
The present investigation was designed to summarize 
what is currently understood about the diagnosis, treat¬ 
ment, and prognosis of patients with EE, and to add to 
this knowledge through an analysis of outcomes of our 
study patients. The first section of this study is a re¬ 
view of the literature which includes an historical per¬ 
spective, data from clinical reports, and in vitro and 
animal model studies. The second section of this paper 
is a review of the case records of 37 patients treated 
for 42 episodes of EE at four Yale hospitals over a 13 
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year period. A descriptive summary of the disease in 
these patients includes the incidence, sources of infec¬ 
tion, presentations, and clinical courses and outcomes. 
This study then attempts to address three major is¬ 
sues within the limitations imposed by a retrospective 
investigation of limited size. First, the data is ana¬ 
lysed with respect to 3 questions concerning the relative 
effectivenesss of different treatment options (the choice 
of antibiotics, the duration of aminoglycoside treatment, 
and the role of surgery). Second, the rates of complica¬ 
tions in patients with certain underlying conditions are 
analysed in an effort to determine prognostic features 
for this disease. Third, the clinical features of 33 pa¬ 
tients, none of whom had relapse of their EE, are comp¬ 
ared to similar data from the 4 patients who suffered 5 
relapses of their disease. The groups are analysed for 
factors which may indicate a low or high risk of relapse 
in EE. 
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MICROBIOLOGY 
Group D streptococci are divisible into enterococ- 
cal and non- enterococcal (.£. bovis and .£. eauinus) 
streptococci. The enterococcal species are: .£. 
faecalis. .£. faecium. .£. durans. and £. avium. .£. 
faecalis. the most prevalent species of enterococcus in 
U.S. clinical isolates, is subspeciated into .£. 
liouefaciens and zvmogenes. .£. faecium is the next 
most prevalent species, and accounts for 5 to 15$ of en¬ 
terococcal isolates (62). 
Sherman (86) first characterized and distinguished 
the enterococcus in 1938. The problem commonlyXencoun- 
tered in clinical microbiology laboratories involves the 
differentiation of enterococcus from .£. bovis. _g. 
bovis. like enterococcus, is resistant to heat and bile, 
but lacks the enterococcus* resistance to high salt con¬ 
centrations. This microbiologic differentiation was 
found to have great clinical significance. 
Enterococci are charactrized like other strepto¬ 
cocci on the basic of hemolysis and Lancefield typing. 
Enterococci can show any type of hemolysis (alpha, beta, 
or none). The streptococcal group-specific antigen (D) 
is a glycerol-techoic acid constituent of the cell wall, 
whereas most Lancefield groups possess a polysaccharide 

group-specific antigen. 
The type-specific antigens, also located in the 
cell wall, consist of carbohydrate that is species spe¬ 
cific in the enterococci. Each species possesses dis¬ 
tinctive 0 antigens and the variability of the antigen 
permits typing within a species. 
THE DISEASE 
Enterococci are members of the indigenous flora of 
the lower gi tract, the female gu tract, and the perine¬ 
um. Their localization to these sites in healthy indivi¬ 
duals is the key to understanding the most common mechan¬ 
isms whereby this bacterium invades the bloodstream. Two 
specific populations have been found to account for the 
majority of cases of EE. The first is older men with 
prostatic hypertrophy, especially those who undergo uro- 
logic instrumentation (including TUR, cystoscopy, ne¬ 
phrectomy, and urethral catheterization and sounding). 
The second population at higher risk is women of child¬ 
bearing age who have had obstetric or gynecologic proce¬ 
dures involving the uterus (including abortion, dilata¬ 
tion and curettage, normal pregnancy, IUD placement, and 
caesarian section.) The mean age of men with the infec¬ 
tion is 59 and that of women is 37 (^0). 
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About 50? of patients with EE have been shown to 
have a probable genitourinary source of infection (docu¬ 
mented gu tract manipulation, trauma, or disease within 3 
months prior to onset of symptoms) (J*0, 52). EE is also 
associated with any disease, manipulation, or operation 
of the biliary or lower gi tract, including hemorroidec- 
tomy, in either sex. There is often a history of a uri¬ 
nary tract infection with enterococci. Although less 
well docmented than .£. bovis. EE is associated with 
cancer of the sigmoid colon. The diagnosis of EE or any 
group D strep endocarditis merits work-up of the gi tract 
unless a clear source of infection already exists (78). 
Less commonly, enterococci have also been cultured 
from the oropharynx. Several literature reports have 
identified infection in the oral cavity as the probable 
source of blood-borne enterococci. Toh (9^) identified 3 
of 8 cases of EE as secondary to dental infections. 
Dietz (16) found that the enterococcus isolated from the 
blood of a patient with EE was identical (by phage typ¬ 
ing) to an enterococcus isolated from the patient's 
teeth, whereas the gi tract yielded an enterococcus of a 
different strain. Similarly, in one of 33 cases of EE 
reported by Geraci and Martin (25), a periapical dental 
abscess was identified as the probable source of infec¬ 
tion. Thus, it appears that oral and dental infections, 
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though more commonly associated with S. viridans endo¬ 
carditis, also increase the risk of enterococcal bacter¬ 
emias and endocarditis. 
There is a higher incidence of EE in post-op pa¬ 
tients (25$ of those with endocarditis have EE), in dia¬ 
betic patients (3 to 5 times more EE than other pa¬ 
tients), and in patients with urologic infections (33$ of 
cases with endocarditis are secondary to enterococcus and 
10$ are secondary to gram negative rods) (13). 
The reported frequency of cases of EE among drug 
addicts with endocarditis ranges from 7$ to 55$ 
(*J, 9,20,73s74,89) • Enterococcus is fifth in a listing of 
the most common microorganisms isolated from narcotic ad¬ 
dicts with IE. Staph, aureus, gram negative bacilli, 
fungi, and non-enterococcal streptococci in that order, 
are more common (9). In one review of 3**** patients, EE 
accounted for 8$ of IE in narcotic addicts (7*0. 
EE in addicts has been found to involve predomi¬ 
nantly the valves of the left side of the heart (9,7*0. 
In a review of 270 cases of endocarditis in drug addicts, 
enterococci involved the aortic valve in 76$, the mitral 
valve in 38$, and the tricuspid valve in 5$ of those 
cases of EE. This contrasts with the overall frequency 
of involvement of these valves in narcotic addicts with 
IE which were: 35$, 30$, and 55$ respectively (9). The 
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mean age of patients with a history of drug abuse with IE 
(about 25 years) is significantly lower than other pa¬ 
tients with IE and the majority are male (9,20). 
Predisposing factors for IE include valvular heart 
disease, congenital cardiac malformations, IHSS, and mi¬ 
tral valve prolapse. In large series of patients with 
IE, a history of heart disease is present in a major pro¬ 
portion of cases (60$) (47,99). In reports of EE, a sig¬ 
nificant percentage of patients also had a predisposing 
cardiac lesion. Four series of patients with EE reveal 
an incidence of prior heart disease ranging from 37$ to 
44$ (44,53,60,94). 
Enterococci are also known to attack normal valves; 
more than 50$ of cases of EE may have no underlying heart 
disease (53). EE affecting previously normal valves is 
more likely to develop as an acute disease process. 
Geraci’s literature review of autopsies in 1954 yielded 
60$ of cases of EE with normal valves (25). 
The pathogenesis of EE has been described in detail 
(79,103A). Platelets adhere to an abnormal valve or en¬ 
docardial surface forming a sterile platelet-fibrin 
thrombus. A transient bacteremia from a gi, gu, or oral 
source, especially after instrumentation, yields circu¬ 
lating bacteria which adhere to the clot, The bacteria 
usually land on the ventricular surface of the aortic 
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valve leaflets and the atrial side of the mitral valve in 
mitral regurgitation because of the low pressure sink in 
these positions resulting from the Venturi effect across 
the valves. Highly adherent organisms, including entero¬ 
cocci and S. viridans are the more frequent causative 
agents of endocarditis. 
The incidence of EE is most commonly reported at 5 
to 15$ of all cases of endocarditis in the literature 
(13,22, 24,25,35,*40,47,65,79) • The documented incidence 
varies between hospitals but there is general agreement 
that the incidence has been steadily increasing in the 
past 3 to 4 decades. EE was diagnosed relatively rarely 
prior to 1945 and the antibiotic era. Since then entero¬ 
cocci have assumed an increasingly significant role in 
the etiology of bacterial endocarditis (BE). The entero¬ 
coccus is now the third most common etiologic agent of 
BE. Non-enterococcal streptococci (about 40$ of endocar¬ 
ditis cases) and staphylococci (about 20$) are more com¬ 
mon. Group D streptococci are responsible for about 40$ 
of streptococcal endocarditis; i>. bovis accounts for 
two-thirds and enterococcus for one third (80). 
A decline in the proportion of cases of BE caused 
by streptococci has been documented by some authors 
(13,65). Large reviews document the current incidence of 
streptococcal endocarditis as 40 to 50$ of all BE cases 
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(22,65,79). 
There is some evidence to indicate a slight incre¬ 
ase or no change in the overall incidence of BE during 
recent decades (98,99). This is attributed to an incre¬ 
ase in susceptibility to endovascular infections produced 
by a marked rise in cardiac surgery, valve replacements, 
and placement of AV fistulas. More patients with rheu¬ 
matic heart disease, atherosclerotic heart disease, and 
congenital heart disease are living longer, thereby in¬ 
creasing the size of the population at risk. Also impor¬ 
tant is a change in the social behavior, with widespread 
self-inoculation and drug abuse now present in this coun¬ 
try. 
In contrast, several sources document a decreasing 
incidence of BE since the antibiotic era (13,42,^7). 
This is accounted for by an increasingly widespread and 
appropriate use of antibiotics in all types of infec¬ 
tions, which minimizes bacteremia, along with more preva¬ 
lent and improved chemoprophylaxis for patients known to 
be susceptible to BE. 
Several explanations have been offered for the in¬ 
creasing incidence of EE. First, there have been changes 
in the host population, specifically an increase in the 
mean age attributed to a longer life span and the result¬ 
ing increase in men requiring urologic procedures 
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(40,47,99). Second, more patients are receiving more and 
better chemoprophylaxis before invasive procedures. Some 
of the antibiotic treatments available, especially those 
commonly used, are more readily bactericidal for other 
organisms, such as .£. vlrldans. Penicillin (used as 
prophylaxis during dental procedures) and cephalosporins 
(commonly used during cardiac surgery and other opera¬ 
tions) (101), do not include enterococcus in their spec¬ 
trum of bactericidal activity. A third possible contri¬ 
buting factor in the rising incidence of EE is the im¬ 
provement in the methodology for identification, result¬ 
ing in more group D streptococci being characterized as 
enterococci. 
More patients have BE caused by n!on-streptococcal, 
non-staphylococcal organisms due to a rise in nosocomial 
infactions,the use of prostheses, invasive procedures, 
and drug abuse. The percentage of patients developing 
streptococcal endocarditis has decreased without a decre¬ 
ase in the number of patients who develop endocarditis 
(109). 
Patients with EE may present with either an acute 
or subacute clinical picture. The versatile nature of 
the enterococcus contrasts with other micro-organisms 
which cause an acute (staphylococci and pneumococci) or 
subacute (£. viridans) endocardial infection, but not 
11 

both. EE is often described as an insidious disease pro¬ 
cess, although patients occasionally die acutely 
(52,107). The symptoms and physical findings are similar 
to those that occur with BE caused by other organisms 
(107). A ten year review of group D streptococcal endo¬ 
carditis at the MGH emphasized the similarity in clinical 
presentation between .£. bovis and EE, despite the fact 
that the disease courses were radically different (60). 
A paucity of "classic peripheral signs" of IE (splinter 
hemorrhages, Osier's nodes, Roth's spots, and Janeway's 
lesions) has Ibeen noted among patients with EE (52). The 
features which may aid in distinguishing EE from other 
types of IE are: a subtle coure (and a longer delay be¬ 
tween onset of symptoms and diagnosis), lower temperature 
elevations (<39.5'C) and fewer and later peripheral man¬ 
ifestations (83). 
12 

TREATMENT 
Bacterial endocarditis is a unique infection in 
that masses of micro- organisms grow in a poorly vascu¬ 
larized vegetation. Phagocytic cells can gain only very 
limited access to the densely packed matrix of fibrin, 
platelets, and nectrotic valve substance. Host defenses 
are thus particularly ineffective in combatting this in¬ 
fection. The crucial prerequisite for cure is prolonged 
bactericidal therapy (32,80). There are only very rare 
clinical reports documenting spontaneous cure of BE or 
cure with static antibiotic therapy. Bacteriostatic an¬ 
tibiotics often produce a clinical remission but have a 
high relapse rate. 
In order to achieve cure in EE, combination antimi¬ 
crobial therapy is probably required. EE is now one of 
few clear indications for therapy with synergistic combi¬ 
nations of antibiotics. The classical regimen of peni¬ 
cillin and streptomycin has been recommended for over 
thirty years. In this section the treatment of EE will 
be discussed beginning with an historical perspective and 
followed by a discussion of the major controversial is¬ 
sues. 
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Prior to the development of antibiotic therapy, pa¬ 
tients with BE almost always succombed to their disease. 
After the introduction of prontcsil in 1935, intensive 
treatment with sulfonamides cured only a small proportion 
of cases. In 1950 T.H. Hunter attributed the discourag¬ 
ing results to his theory that bacteriostasis was insuf¬ 
ficient to effect a cure in BE (32). After 19*15, peni¬ 
cillin became the standard therapy for BE, at first with 
very low doses (less than 300 thousand units per day). 
Within a few years, reports were documenting that even 
prolonged therapy with large amounts of penicillin were 
ineffective in curing a small but significant percentage 
of streptococcal endocarditis. Enterococci were usually 
the infecting organisms in these cases (32,35). 
In 19*17 T.H. Hunter published the first clinical re¬ 
port on the use of streptomycin in patients with BE. Of 
5 patients with EE, *1 failed streptomycin therapy and one 
was cured with a combination regimen: streptomycin and 
penicillin used together because "the organism appeared 
to be more susceptible in vitro to a combination of the 
two than to either alone". In conclusion, Hunter dis¬ 
cussed his theory that two antibiotics "acting in the 
same time but in different manners" may successfully kill 
organisms in a "temporary phase of resistance" to one of 

the antibiotics (33). 
Clinically documented cures of EE with the concur¬ 
rent administration of penicillin and streptomycin appe¬ 
ared soon thereafter (76). In vitro data showed that 
these antibiotics acted synergistically against the en¬ 
terococcus and confirmed the bactericidal nature of this 
combination (3*0. 
Enterococci are less susceptible than other strep¬ 
tococci to almost all classes of antimicrobial agents 
(58). The MIC of penicillin against enterococci ranges 
from 0.8 to 25 mcg/ml, with a median of 2.0 mcg/ml (58). 
The majority of non-enterococcal streptococci are inhi¬ 
bited by less than 0.1 mcg/ml of penicillin (51). 
Enterococci are tolerant to the bacteriostatic ac¬ 
tion of penicillins; the ratio of MBC:MIC is often great¬ 
er than 32 (107). Relative resistance to penicillins and 
cephalosporins is probably intrinsic to enterococci. 
This is supported by the fact that enterococcal sensitiv¬ 
ity to penicillin is not changing over time, and MIC's of 
penicillin to enterococci isolated from antibiotic-virgin 
populations are similar to those found in the U.S. and 
Europe (58). 
A few cases of EE have been reported from the 
19^0’s and 1950’s in which penicillin alone or in combi¬ 
nation with probenecid has resulted in cure. The pa- 
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tients received 12.5 to 1852 mu of penicillin total dose 
for 28 to 66 days, often with very high blood levels of 
penicillin. In 1954, Geraci reported 18 patients treated 
with penicillin, of which 10 were treatment failures and 
7 were cured at 9 month to 8 year follow-up (25). 
Overall, the failure rate in patients treated with peni¬ 
cillin alone is very high (35,76). 
Ampicillin is at least one tube dilution more ac¬ 
tive against enterococci than is penicillin. In addi¬ 
tion, enterococci are often less tolerant to ampicillin 
as compared to penicillin (107). The fact that ampicil¬ 
lin has been shown to be bactericidal at almost the same 
concentration at which it is bacteriostatic (7,68) is a 
significant factor in favor of its use in BE. In vitro 
data suggest ampicillin may be a valuable agent against 
enterococci. A review of 135 strains of enterococci 
tested against ampicillin by eight investigators showed 
more than 90? of strains to be inhibited by ampicillin at 
clinically achievable concentrations (6). 
There are reports of cure with ampicillin alone. 
Beaty et al (6) reported one case cured with high dose 
ampicillin (8 gm per day parenterally and 6 gm per day 
orally for 4 weeks). Other sporadic reports (reviewed in 
6,41) confirm that ampicillin can affect a bacteriologic 
cure in this disease. Supporting the in vitro and clini- 
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cal evidence that combination therapy may not always be 
necessary for cure of EE, Tight et al (92) reported suc¬ 
cessful treatment of rabbits with EE with injections 
of ampicillin into subcutaneous chambers. But occasional 
treatment failures have also been reported (6,53). The 
latter report describes frank failures of therapy with 
ampicillin in doses of 6-12 gm. per day. These patients 
were then cured with penicillin and streptomycin. The 
potential advantages of ampicillin therapy (fewer serious 
side effects and significant financial savings) over 
standard combination regimens provide an impetus for 
further investigation of the use of ampicillin alone in 
EE. At present, most authors emphasize that ampicillin 
does not appear to be comparable in efficacy to a peni¬ 
cillin-streptomycin regimen. (6,-41,53)- 
SYNERGISTIC ANTIBIOTIC COMBINATIONS 
Synergy is a controversial topic. Two antibiotics 
are considered synergistic when the MIC of each drug is 
at least four times lower in combination compared to the 
MIC of that drug alone (2). Alternatively, synergy is 
established when the MBC of each drug in combination is 
one fourth or less than the MBC of each drug used indivi¬ 
dually (108). In this study, the term synergy will in- 
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elude either definition. 
Synergy curves have convincingly demonstrated a 
significant increase in killing potential with combina¬ 
tion therapy (32,96,99). Synergy has been demonstrated 
for several penicillin-aminoglycoside combinations. 
However, there have been reports of treatment failures 
with this regimen (^7). In vitro tests have shown that 
penicillin and streptomycin are not synergistic against 
all strains of enterococci (35). 
In 197C Standiford et al and Moellering et al 
(61,88) suggested that clinical isolates of enterococci 
were divisible into two groups: moderately resistant and 
highly resistant (MIC > or = 2000 meg/ml) to streptomy¬ 
cin. They found a correlation between strains exhibiting 
a high level of resistance to streptomycin and the ab¬ 
sence of synergy of the penicillin-streptomycin combina¬ 
tion in those strains. Moellering suggested that this 
observation permitted replacing the complicated and con¬ 
troversial direct test of synergy with the simpler test 
for high level aminoglycoside resistance. 
Several studies have assessed the prevalence of en- 
terococcal strains possessing high level streptomycin re¬ 
sistance. Standiford et al (88) showed that 19 (29$) of 
M9 strains were resistant to penicillin- streptomycin 
synergy and this correlated with high level streptomycin 
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resistance. Moellering et al (61) found that 80$ of 26 
wound strains, M0$ of 27 blood strains, and MO $ of 103 
urine strains of enterococci exhibited high level resis¬ 
tance to streptomycin. 5M$ of blood isolates from the 
clinical microbiology lab at the MGH demonstrated high 
level streptomycin resistance (8). 
These in vitro observations have been expanded to 
include other aminoglycosides. Standiford et al (88) 
showed that penicillin and kanamycin, though synergistic 
against some enterococcal strains, did not display syner¬ 
gy against enterococci highly resistant to kanamycin (MIC 
> or = 25,000 mcg/ml). Up to 20$ of strains are resis¬ 
tant to 2000 mcg/ml of kanamycin (61). More recently, 
M9$ of blood isolates were found to possess high level 
kanamycin resistance (8). Prevalences of enterococcal 
strains highly resistant to streptomycin and kanamycin 
have been reported to be 25-50$ by four other groups in 
different cities (reviewed in 58). The prevalence of 
streptomycin resistant enterococci appears to be increas¬ 
ing (Ml,58). 
Very few strains of .£. faecalis have resistance to 
high concentrations of gentamicin, amikacin, tobramycin, 
or netilmicin (58). Consequently, much investigation has 
centered on these alternatives to streptomycin and kana¬ 
mycin. 
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i>. faecium has higher MIC’s to penicillin (2-64 
mcg/ml) than faecalis (1-4 mcg/ml) (107). Resistance 
to synergy begins with the organism’s resistance to peni¬ 
cillin (62). faecium is more resistant to a number 
of combinations of penicillin and an aminoglycoside than 
is .£. faecalis (26). Among .£. faecium strains, about 
50? and 30? show high level resistance to streptomycin 
and kanamycin respectively. The only penicillin- 
aminoglycoside combinations that are consistently effec¬ 
tive against .£. faecium are penicillin-gentamicin and 
penicillin-streptomycin (without high level resistance) 
(62). Pencillin and tobramycin are not synergistic in 
vitro or in vivo against strains of faecium (107). 
Consistent with these results, a therapeutic failure of 
ampicillin and tobramycin has been reported recently in a 
patient with .£. faeclum endocarditis (26). 
Experimental data from the rabbit endocarditis mo¬ 
del have shown that penicillin and streptomycin, penicil¬ 
lin and gentamicin, and penicillin and sisomicin reduce 
titers of enterococci in vegetations more rapidly than 
penicillin alone when the enterococcus was inhibited by < 
2000 mcg/ml of streptomycin. When the strains show re¬ 
sistance to 2000 mcg/ml of streptomycin, penicillin and 
gentamicin or penicillin and sisomicin demonstrate syn¬ 
ergistic killing in vivo, but penicillin and streptomycin 
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do not. This study is unusual in that it shows a close 
correlation between the results of in vitro and in vivo 
studies which are rarely comparable (10). Other animal 
studies have supported these results (^1). 
The same synergistic killing activity was demon¬ 
strated in the rabbit model of endocarditis with .£. 
faecium: a faster reduction of bacterial titers in vege¬ 
tations with the use of penicillin and streptomycin or 
gentamicin than with penicillin alone or penicillin plus 
netilmicin (iJI). 
The correlation of high level resistance to an ami¬ 
noglycoside with lack of synergy between penicillin and 
that aminoglycoside and the clinical relevance of this 
have been challenged. In 1962 Tompsett and Pizette stu¬ 
died enterococci from four patients cured of endocarditis 
and concluded that neither MIC's nor synergy tests were 
predictive of clinical results with combination therapy. 
More recently, Tompsett and Berman noted that if up to 
^0? of enterococcal strains possess high level streptomy¬ 
cin resistance , and if in fact this correlates with ab¬ 
sence of synergy to combination therapy and therefore 
with poor clinical results, failure of penicillin- 
streptomycin therapy should be common. Yet their search 
of the literature in 1977 yielded only three documented 
failures of this regimen, two of which were successfully 
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retreated with the same drugs. The one treatment failure 
with penicillin and streptomycin in their study involved 
a strain which did not exhibit high level streptomycin 
resistance and was synergistically inhibited by penicil¬ 
lin and streptomycin (96). 
Roberts treated 1*4 patients with 6 weeks of peni¬ 
cillin and streptomycin. Thirty to forty percent of the 
enterococcal strains were highly streptomycin resistant, 
yet there were no differences in the clinical course (no 
relapses) between the streptomycin resistant and sensi¬ 
tive groups. He raised a question, however, of whether 
vegetations might be sterilized more quickly with peni¬ 
cillin and gentamicin in the highly streptomycin resis¬ 
tant strains (96). 
There are several controversial issues in the con¬ 
cept of antibiotic synergy in EE. First, it is not pos¬ 
sible to accurately predict the presence or absence of 
synergy without in vitro testing. Watanakunakorn (100) 
tested 33 strains of enterococci for synergy and found 
that all were synergistically inhibited by penicillin and 
gentamicin, but 13 strains lacked synergy to penicillin 
(20 meg) and streptomycin (20 meg). However, only four 
of these strains were hightly resistant to streptomycin. 
Serra et al (83) found that in only five of 15 strains 
resistant to 2000 mcg/ml of streptomycin was penicillin- 
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streptomycin synergy absent. And in 3 other strains sen¬ 
sitive to streptomycin, the combination also demonstrated 
a lack of synergy. 
Second, even if the in vitro data is accurate, do 
treatment failures with penicillin and streptomycin 
occur? Recent reports have documented a few failures but 
they may be very rare. High dose long term penicillin 
therapy may have cured some of the patients treated with 
penicillin and streptomycin for EE caused by strains 
highly resistant to streptomycin (35,^1). Third, do 
treatment failures correlate with in vitro data (high 
level resistance and absence of synergy) for that organ¬ 
ism? As noted above, the number of treatment failures is 
significantly less than the reported incidence of high 
level streptomycin resistance. In addition, Tompsett and 
Pizette (97) reported the cure of a patient with penicil¬ 
lin and streptomycin despite the organism's high level 
resistance to streptomycin. Roberts (96) reported sever¬ 
al more patients treated successfully. 
PENICILLIN-GENTAMICIN 
Penicillin and gentamicin have been suggested as an 
alternative synergistic combination therapy for entero- 
coccal endocarditis. In vitro studies have not demon- 
23 

strated high level resistance to gentamicin in any enter- 
ococcal strains (59). For example, Serra et al (83) stu¬ 
died 15 enterococcal strains and found synergy to ampi- 
cillin or penicillin and streptomycin in 7 (^7?), while 
the penicillin or ampicillin and gentamicin combination 
was synergistic in 100? of the strains. 
However, one strain which permitted no synergistic 
killing with ampicillin-gentamicin in vitro twice caused 
treatment failures with this regimen. The organism did 
not exhibit high level resistance to gentamicin. A new 
mechanism, a defect in the uptake of gentamicin in the 
presence of penicillin, is thought to explain the lack of 
synergy in this case. Penicillin and tobramycin (which 
did not show a defect in uptake) showed synergy in kil¬ 
ling the organism, and this combination cured the patient 
(59). 
Enterococcal strains resistant to penicillin- 
gentamicin synergy seem to be rare, but there is some 
concern that the lack of high level gentamicin resistance 
may be a reflection of the infrequent use of gentamicin 
for enterococcal infections (61). Three strains of en¬ 
terococci with transmissible high level resistance to 
gentamicin were recently isolated in France. The mechan¬ 
ism of resistance is thought to require two amino¬ 
modifying enzymes: a 6’ acetyl transferase and a 2" phos- 

photransferase (58). 
Although the in vitro data indicates a low inci¬ 
dence of high level resistance to gentamicin as compared 
to streptomycin and kanamycin, the clinical effectiveness 
of penicillin and gentamicin therapy is not well docu¬ 
mented. Weinstein and Moellering (103) treated four pa¬ 
tients with enterococcal endocarditis with penicillin and 
gentamicin for 25 to ^2 days with a 100? cure rate. One 
patient's organism displayed high level resistance to 
streptomycin. However, Wilson et al (112) reported ^ re¬ 
lapses in patients receiving this combination. Some au¬ 
thors believe that clinical results do not indicate a 
clear choice of penicillin-gentamicin over penicillin- 
streptomycin, even with endocarditis caused by enterococ¬ 
ci resistant to 2000 mcg/ml of streptomycin (39,52). 
The concept of penicillin-gentamicin synergy has 
gained support from in vivo studies in the rabbit endo¬ 
carditis model. With enterococci susceptible to 2000 
mcg/ml of streptomycin, the combination of penicillin and 
gentamicin reduced the bacterial titers more rapidly than 
penicillin alone. The rate of kill was unaffected by the 
addition of steptomycin to penicillin when the organisms 
displayed high level streptomycin resistance. 
Penicillin-gentamicin combinations increased the kill 
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rate in all cases (10). Another in vivo study corrobo¬ 
rated the evidence that penicillin-gentamicin are more 
effective than penicillin-streptomycin in destroying vi¬ 
able enterococci (highly resistant to streptomycin) in 
cardiac vegetations (31). 
MECHANISM OF SYNERGY 
A number of studies have investigated the mechanism 
of penicillin- aminoglycoside synergy against enterococ¬ 
ci. In 1951 Robbins and Tompsett speculated that cure of 
the infection through synergistic action of two antibiot¬ 
ics could be the result of two mechanisms: (1) the elim¬ 
ination by the second antibiotic of variants in the bac¬ 
terial population which are resistant to the first agent, 
or (2) "the activity of one agent upon organisms weakened 
by the other agent" (76). 
Hewitt et al (29) postulated that enterococcal 
spheroplasts are produced in the presence of penicillin 
and then subsequently destroyed by an aminoglycoside. 
However, several studies have shown that penicillin must 
be simultaneously present in order to achieve synergistic 
killing of enterococci. 
It is now widely held that the mechanism of synergy 
is related to the increased susceptibility of enterococci 
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to the aminoglycoside after inhibition of cell wall syn¬ 
thesis by penicillin. Killing is primarily attributed to 
the action of the aminoglycoside. Spheroplasts of Staph. 
aureus and Pseudomonas aeruginosa induced by penicillin 
were found to be more susceptible to gentamicin than were 
the parent bacteria (100). Other studies recently re¬ 
viewed by Moellering (59) have demonstrated that entero¬ 
cocci do not take up significant amounts of Cl^-labelled 
streptomycin and gentamicin unless a cell wall active 
agent is also present. The enhancement of aminoglycoside 
uptake coincides with the killing of enterococci. 
Antimicrobial agents which fail to produce synergy in 
combination with an aminoglycoside (chloramphenicol, er¬ 
ythromycin, tetracycline, and colistin) do not increase 
aminoglycoside uptake by the organism. Thus, the cell 
wall of the enterococcus appears to be the barrier to up¬ 
take of and killing by aminoglycosides. 
Two additional mechanisms may account for high lev¬ 
el resistance to aminoglycosdes and for resistance to 
penicillin-aminoglycoside synergy. Chromosomal mutations 
that cause ribosomal resistance to streptomycin (115) 
probably account for only a minority of cases (58). A 
high level of resistance is more frequently the result of 
plasmid mediated enzymes that modify streptomycin, kana- 
mycin, or amikacin (M5). 
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In vitro data indicate that .£. faeeium. unlike 
other enterococci, are consistently resistant to syn¬ 
ergistic killing by penicillin in combination with kana- 
mycin, tobramycin, sisomicin, and netilmicin. A recent 
study suggests that this resistance is due to enzyme in¬ 
activation of the aminoglycoside by 6 acetyl transferase, 
which is either plasmid or chromosomally mediated (58). 
OTHER ANTIMICROBIAL AGENTS 
Other antibiotics have been investigated as less 
toxic and/or more effective alternatives to penicillin- 
streptomycin and penicillin-gentamicin. All cell wall 
active agents (including cycloserine, bacitracin, vanco¬ 
mycin, benzypenicillin, ampicillin, amoxicillin, carbeni- 
cillin, the semisynthetic penicillinase resistant peni¬ 
cillins, and the cephalosporins) have been shown to be 
capable of producing synergistic killing of enterococci 
in combination with an aminoglycoside (58). In vitro and 
clinical data concerning the efficacy of several of these 
agents will be presented. 
Ampicillin in combination with an aminoglycoside 
appears very effective in treating EE. Some authors sug¬ 
gest substitution of ampicillin for penicillin when peni¬ 
cillin-aminoglycoside synergy is inadequate (107). When 
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ampicillin, penicillin G, erythromycin, and cephalothin 
were tested against 20 enterococcal strains, only ampi- 
cillin killed all of the strains (87). One review (21) 
reports ampicillin was bactericidal against only 17$ of 
20 enterococcal isolates whereas the combination of ampi- 
cillin and streptomycin demonstrated synergy at all con¬ 
centrations and killed 95$ of the isolates at high con¬ 
centrations. Despite the fact that enterococci are more 
sensitive to ampicillin than to penicillin, clinical re¬ 
sults have teen comparable with both regimens (penicillin 
or ampicillin and an aminoglycoside). There is no clear 
evidence to recommend one regimen as more effective ther¬ 
apy than the other. 
As with penicillin, enterococci are tolerant to ce¬ 
phalosporins (87). Cephalosporins, alone or in combina¬ 
tion with streptomycin, have been associated with treat¬ 
ment failures, both in clinically achievable concentra¬ 
tions in experimental animals (1) and in patients (69). 
In vitro synergy has been demonstrated between cephalos¬ 
porins and streptomycin against the enterococcus (21). 
However, other in vitro studies have shown that cepha¬ 
lothin is not effective against enterococci (108). Quinn 
et al (68) showed the median MIC of cephalothin for 17 
strains of enterococci to be greater than 36. This was 
in the range of only the MIC's for the penicillinase re- 
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sistant penicillins (methicillin >41, oxacillin >44, 
nafcillin >16) whereas the MIC's for penicillin, ampicil- 
lin, and vancomycin ranged from 1.8 to 3.6. Synergy of 
cephalothin with penicillin appears to occur only at very 
high concentrations of cehpalothin, and then does so only 
minimally (87). Cephalothin should not be used for the 
treatment of EE. 
Vancomycin is the drug of choice for EE in patients 
who cannot tolerate a penicillin. However, published re¬ 
ports of clinical experiences with vancomycin therapy in 
EE are limited. The interpretation of clinical results 
is made more difficult in many cases by the fact that pa¬ 
tients are often initially treated with penicillin or am- 
picillin before developing a reaction which necessitates 
the replacement of penicillin with vancomycin. 
Like other cell wall active antibiotics, vancomycin 
is usually bacteriostatic against enterococci when used 
alone (46). Vancomycin was the third most active agent 
(after ampicillin and penicillin) against enterococci, 
and the three agents were the only ones uniformly active 
against nearly all strains in large scale in vitro test¬ 
ing with 382 strains of enterococci (93). Watanakunakorn 
(102) reported no bactericidal activity of vancomycin al¬ 
one (at 20 mcg/ml-the equivalent of peak serum concentra¬ 
tion of 1 gm. iv vancomycin) against 8 enterococcal 
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strains despite relatively low MIC’s (92$ of strains be¬ 
tween 0.78 and 3*12 mcg/ml, all < 6.25 mcg/ml). 
Friedberg (23) first reported the successful treat¬ 
ment of EE with vancomycin in 4 patients (no treatment 
failures) in 1968. The patients received 2-3 gm. 
vancomycin per day for 15-26 days but 3 of the patients 
also received penicillin and streptomycin intially. Hook 
et al (102) reported cure of one patient with 2 gm. per 
day of vancomycin for 4 weeks. 
In vitro studies have documented synergy with van¬ 
comycin and aminoglycoside combinations comparable to 
penicillin-aminoglycoside synergy for enterococci. 
Mandell et al (54) showed marked synergy between strepto¬ 
mycin and vancomycin against 18 of 20 strains tested. 
The combination of streptomycin at 12.5 mcg/ml and vanco¬ 
mycin at 2.5 mcg/ml was bactericidal for 13 of the 20 
strains. Westenfelder et al (106) reported synergy of 
vancomycin and streptomycin against 12 of 18 isolates, 
including a strain against which vancomycin was only bac¬ 
teriostatic and penicillin-streptomycin lacked synergy. 
Several cures with vancomycin-aminoglycoside combi¬ 
nations have been reported. One patient was cured with 
vancomycin and streptomycin after a ten day course of 
penicillin and a total treatment period of 6 weeks (106). 
Cook (15) reported successful therapy of a patient with 
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vancomycin for 6 weeks and streptomycin for the last 
week. One patient treated with vancomycin and gentamicin 
died during therapy and 2 others were cured with this 
combination. One received 25 days of vancomycin and gen¬ 
tamicin after 7 days of penicillin, and the other re¬ 
ceived 36 days of vancomycin with 15 days of gentamicin. 
The doses of vancomycin and streptomycin were 1-2 and 1 
gm per day respectively. 
Vancomycin and either streptomycin or gentamicin 
are the recommended treatment regimens for use in pa¬ 
tients with a history of penicillin hypersensitivity. 
This is the only other antibiotic combination besides 
penicillin and an aminoglycoside with proven efficacy in 
EE. Experience with the use of alternatives to pencillin 
in patients with EE is limited and therefore penicillin 
is usually continued in patients who have minor hypersen¬ 
sitivity reactions or who have an equivocal history of a 
previous reaction (112). Desensitization through gradu¬ 
ally increasing the dose of penicillin is the other ac¬ 
cepted method of treating EE. Most clinicians recommend 
the desensitization approach when penicillin is a key 
component of the treatment regimen (28), as in EE. This 
approach has been successful in the majority of patients 
with a history of hypersensitivity to penicillin (41). 
The procedure either desensitizes patients to penicillin 
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or simply acts as a skin test to determine who is at risk 
for anaphylaxis. Substitution of a cephalosporin for 
penicillin is not recommended because of the high MIC’s 
of cephalosporins to enterococci, the reported treatment 
failures, and the potential for hypersensitivyity reac¬ 
tions in patients with penicillin allergy. 
The important question of synergy against entero¬ 
cocci between anti-staphylococcal antibiotics and amino¬ 
glycosides is not completely resolved. Some patients 
with EE may require simultaneous treatment for a separate 
staphylococcal infection or for mixed infections. Other 
patients, in whom IE is suspected (especially heroin ad¬ 
dicts) should receive empiric coverage for both staphylo¬ 
cocci and enterococci. Thus, the question is whether a 
regimen consisting of a penicillinase-resistant penicil¬ 
lin and an aminoglycoside would include the enterococcus 
in its spectrum. 
Enterococci are known to be more resistant to oxa¬ 
cillin than to penicillin or ampicillin: median MIC's 
were 50, 3«1» and 1.6 mcg/ml respectively (reviewed in 
56). Despite this, several studies have demonstrated 
synergy between nafcillin or oxacillin and gentamicin 
against some enterococcal strains (112). One group re¬ 
ported oxacillin and gentamicin synergy against 27 (80$) 
of 3^ strains and the killing of 100$ of strains by this 
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combination with a clinically achievable concentration 
(56). 
However, in vivo studies of EE in the rabbit endo¬ 
carditis model (48) have shown low cure rates (sterile 
valves at autopsy) after treatment with nafcillin, oxa¬ 
cillin, or methicillin in combination with gentamicin. 
No difference in effectiveness between the different com¬ 
binations despite markedly different MIC’s was found. 
The same strain was used in previous in vivo studies of 
penicillin and gentamicin demonstrating 100 survival 
rates. It was concluded that combination of a penicilli¬ 
nase-resistant penicillin and gentamicin is not effective 
in the treatment of EE in the rabbit model. Host authors 
now recommend the triple antibiotic regimen of penicillin 
G, a penicillinase-resistant penicillin, and an aminogly¬ 
coside, as initial therapy in patients such as heroin ad¬ 
dicts with presumed BE of unknown etiology. This safely 
covers staphylococci, streptococci including enterococci, 
and gram negative organisms (48,112). 
In the search for better therapeutic agents to cure 
EE, broad spectrum antibiotics have received attention. 
In vitro erythromycin is not bactericidal against entero¬ 
cocci with or without the addition of streptomycin (87). 
Resistance to erythromycin appears to be an acquired 
characteristic since no erythromycin resistant strains 
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were found among Solomon Islanders, none of whom had pri¬ 
or exposure to the antibiotic (58). The susceptibility 
of enterococci to erythromycin as well as to other anti¬ 
biotics (tetracycline, streptomycin, chloramphenicol, and 
bacitracin), though not to penicillin, is decreasing 
(93). Erythromycin was highly active in inhibiting about 
one half of enterococcal strains in one study but showed 
a very wide variation in activity (93). 
Resistance to chloramphenicol and tetracycline was 
demonstrated in 22% and 78$ respectively of enterococcal 
strains at the MGH in 1979. The resistance of enterococ¬ 
ci to erythromycin, chloramphenicol, and tetracycline has 
been shown to be mediated by plasmids (58). Combinations 
of aminoglycosides with cell membrane active agents 
(e.g., polymixins) or with protein synthesis inhibitors 
(e.g., chloramphenicol, macrolides, and tetracycline) do 
not yield synergy against enterococci. None of these 
agents are recommended for the treatment of EE (58). 
DURATION OF THERAPY 
The standard regimen used in EE is high-dose peni¬ 
cillin G (15-20mu) iv each day with streptomycin or gen¬ 
tamicin for 4 to 6 weeks. In the penicillin-allergic pa¬ 
tient desensitisation is recommended or, if this fails, 
35 

vancomycin plus streptomycin or gentamicin is used. 
Recommended doses include at least 20mu of penicillin, 12 
gm of ampicillin, 1 gm of streptomycin, 3 mg/kg of gen¬ 
tamicin , and 2 gm of vancomycin each day (Ml). In some 
centers, the six week treatment regimen has become the 
accepted standard in EE, largely on the basis of anecdo¬ 
tal reports, retrospective studies, and tradition. 
Tompsett and Berman (96) challenged this practice 
and recommended streptomycin and penicillin treatment for 
M weeks based on their results. They treated 13 patients 
with this regimen. Two patients died during treatment, 
two died within a few months of therapy (blood cultures 
negative), and 9 patients (69%) were cured. Sande (80) 
reports a personal communication from W. Wilson concern¬ 
ing 68 patients with EE successfully treated with four 
weeks of penicillin and streptomycin. Earlier, Geraci 
and Martin (25) treated patients with penicillin (5-15 mu 
QD) and streptomycin for 4 weeks and cured two patients 
but two patients relapsed. The relapses may have been 
attributable to the low dose penicillin. 
A recent review, discussing the issue of duration 
of therapy, concluded: "It is possible that M weeks of 
therapy may be as effective as 6 weeks of treatment” 
(Ml). The issues of how long to treat, which factors 
identify a group at higher risk of relapse, and whether 
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this group should receive a longer than standard treat¬ 
ment regimen have not been resolved. Six week therapy is 
currently recommended for patients with "complicated 
courses" or prosthetic valve EE. 
There have been few reports of treatment of pa¬ 
tients with relapse of EE after appropriate treatment. 
Combination therapy may fail to cure EE despite satisfac¬ 
tory SBC titers and absence of underlying host illness 
(107). Most authors suggest a second antibiotic course 
for 6 to 8 weeks, possibly using a different aminglyco- 
side and either switching to ampicillin or using larger 
doses of penicillin (40-80 mu) (52,107). One author sug¬ 
gests early surgical intervention if a patient has al¬ 
ready failed optimal therapy once (17) in an attempt to 
avoid the statistically likely occurence of further com¬ 
plications. 
ANTIBIOTIC SIDE EFFECTS 
There is a significant incidence of adverse reac¬ 
tions associated with 4 to 6 weeks of parenteral penicil¬ 
lin or vancomycin and aminoglycoside therapy. Mandell 
(53) reported 15 of 38 patients (40$) with EE developed 
reactions to penicillin, streptomycin, or both. One au¬ 
thor has noted that the high incidence of antibiotic tox- 
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icity associated with EE in particular may be partially 
due to the older age (mean=60 years) of these patients in 
comparison with those having other types of endocarditis 
(112). The major toxicities of the antibiotics commonly 
used in EE are discussed briefly here. 
From 0.7 to 10? of patients treated with penicillin 
G for a period of weeks develop hypersensitivity reac¬ 
tions (27). A 10$ incidence has been reported. (41). 
Mandell (53) reported that 13$ of 38 patients developed 
an adverse reaction to penicillin. Although none re¬ 
quired a change in antibiotic therapy, one patient died 
of a fatal gi vasculitis. Moellering (60) described 23 
patients with endocarditis who received penicillin or am- 
picillin for greater than one week. One patient devel¬ 
oped a fever and two developed skin rashes. Patients are 
usually continued on penicillin despite the occurence of 
rash and fever. Acute anaphylaxis, the most serious tox¬ 
icity, occurs in 0.015$ to 0.04$ of patients treated with 
penicillin; 0.002$ die (27). 
Ampicillin is known to cause a skin rash in 9$ of 
patients who receive the drug versus about 4$ treated 
with penicillin. GI complaints, especially diarrhea, al¬ 
so occur more frequently (about 25$) with ampicillin. 
In the past, vancomycin has been associated with 
thrombophlebitis, fever, nephrotoxicity, and hearing 
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loss. In recent studies the drug is usually well toler¬ 
ated. The change is probably related to differences in 
manufacturing (30,60). A recent review of 25 reports of 
vancomycin therapy for endocarditis cites a rise in serum 
creatinine (reversible) in 2 cases and 3 cases of rash, 
phlebitis, or fever. Three of 10 patients followed with 
serial audiograms developed high frequency hearing loss 
which was reversible in one patient. The ototoxicity was 
associated with renal insufficiency (creatinine 1.3—1.6) 
(41). The ototoxicity and nephrotoxicity associated with 
vancomycin are reported to occur predominantly with high 
dosage regimens (27). 
Importantly, vancomycin has been reported to poten¬ 
tiate the toxicity of aminoglycosides in animal studies 
(27). Little clinical data is available on this subject. 
The most frequently observed side effects of strep¬ 
tomycin are vestibular and auditory disturbances. 
Vestibular dysfunction is more common and is dose relat¬ 
ed. Approximately 25? of patients develop vestibular 
toxicity while receiving 1 gm each day for prolonged per¬ 
iods (60 to 120 days). A decrease in hearing was noted 
in 4? to 15? receiving streptomycin for at least one 
week. Deafness is a rare complication (27). Mandell 
(53) reported ototoxicity in 8 of 36 patients (22?), all 
of whom had received at least 2 gm each day for 14 days 
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before onset of symptoms. Tompsett (96) treated 15 pa¬ 
tients with normal renal function with 20 mg/kg/day 
doses, always < 1 gm, for 4 weeks and noted no vestibular 
toxicity. In Koenig and Kaye's study of 18 patients, 5 
developed symptoms of either vertigo or hearing loss. 
There was no significant difference in age or total doses 
of streptomycin between symptomatic and non-symptomatic 
patients (44). Hypersensitivity reactions (skin eruption 
and eosinophilia) are also known to occur with streptomy¬ 
cin (27). Streptomycin causes renal dysfunction in only 
1I? of patients and it is often preferred over gentamicin 
because of the latter's higher rates of renal toxicity. 
Gentamicin is the most nephrotoxic of the commonly 
used aminoglycosides. Some degree of renal impairment 
occurs in 2-10? of patients, most often about 4? (27). 
In a recent large study of EE (113), most patients treat¬ 
ed with gentamicin developed a rise in serum creatinine. 
The series demonstrated that only 2 of 9 patients receiv¬ 
ing < or = 3mg/kg showed a rise in creatinine (mean 0.85 
mg/100 ml) whereas 11 of 11 patients receiving > 
3mg/kg/day developed renal insufficiency (mean creatinine 
1.35). Thus, 3mg/kg/day of gentamicin was recommended as 
an effective therapy which appears less toxic than 
5mg/kg/day. This dosage is also recommended by Wilkowske 
(107). Vestibular toxicity is also reported with gentam- 

icin, at an approximate incidence of 1 to 5? (107). 
Prolonged therapy and excessively high trough concentra¬ 
tions correlate with the incidence and severity of renal 
toxicity and ototoxicity. Elderly patients and those 
with shock, dehydration, renal disease, or oliguria are 
at higher risk of gentamicin renal toxicity. 
Most authors recommend following serum concentra¬ 
tions of aminoglycosides and vancomycin to avoid exces¬ 
sively high levels and greater likelihood of toxicity. 
In the treatment of BE, serum bactericidal concentration 
(SBC) titers are usually monitored and drug doses altered 
accordingly. Some investigators suggest keeping the SBC 
at 1:8 in an effort to insure bactericidal drug concen¬ 
trations but reduce the potential for toxicity (41). The 
use of the SBC as a parameter of effectiveness of therapy 
remains controversial. Experimental data indicate a peak 
serum activity of 1:8 or greater should be bactericidal 
for the organism (some investigators include 1:4 titers 
as adequate therapy). A low titer at the nadir of drug 
concentration does not appear to indicate inadequate 
therapy. The SBC remains the only test which seems to 
correlate with bacteriologic response in experimental 
studies and in patients (41). However, a recent analysis 
of the literature on endocarditis failed to document a 
significant association between serum inhibitory concen- 

tration (SIC) or SBC titers of 1:8 or more and survival 
or bacteriologic cure (1H). Interpretation of the titer 
is complicated not only because of doubt about its sig¬ 
nificance, but also because different methods are used to 
determine SBC titers, and the activity is measured at 
different times relative to the antibiotic dosing sche¬ 
dule. 
SUMMARY 
Single drug treatment of EE usually results in re¬ 
lapse, although some cures with axnpicillin or vancomycin 
alone have been reported. Combination therapy is indi¬ 
cated. Penicillin or ampicillin and streptomycin have 
been the first line regimen used for over 30 years. The 
significance of streptomycin resistance among enterococci 
is unclear, but most investigators recommend treating di¬ 
sease caused by highly resistant organisms with penicil¬ 
lin or ampicillin and gentamicin. 
Several different clinical approaches to the treat¬ 
ment of EE are expressed in the literature. Some clini¬ 
cians routinely use gentamicin in combination with a pen¬ 
icillin for all cases of endocarditis while others recom¬ 
mend this regimen only for those strains highly resistant 
to streptomycin (80). Moellering et al (62) have recom- 

mended treating enterococcal endocarditis with penicillin 
and gentamicin in two situations: (1)infections caused 
by organisms exhibiting a high level of resistance to 
streptomycin and kanamycin, and (2)initial therapy before 
synergy and sensitivity test results are available (112). 
Alternatively, treatment for highly streptomycin- 
resistant organisms could be initiated with penicillin 
and streptomycin and, if the SBC is < 1:8 even after in¬ 
creasing the penicillin dose to 40 mu per day, then gen¬ 
tamicin would be substituted for streptomycin. Kaye sug¬ 
gests choosing the therapy for streptomycin sensitive or¬ 
ganisms based on whether nephrotoxicity (more likely with 
gentamicin) or vestibular toxicity (more likely with 
streptomycin) is of greater clinical significance in a 
given case (41). The importance of penicillin-gentamicin 
therapy will be clarified through more clinical studies 
and better correlation of in vitro data with treatment 
results. 
Initial clinical results with vancomycin and an am¬ 
inoglycoside are encouraging. This is the only recom¬ 
mended treatment for patients who cannot tolerate peni¬ 
cillin. Due to the lack of significant clinical experi¬ 
ence with this regimen, however, it is currently only re¬ 
commended for use in that situation. 
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COMPLICATION AND CURE RATES 
The complications of IE have been well described. 
Robinson (77) compared the cause of death in over 20,000 
autopsies between pre-antibiotic years (1933-38) and 
post-antibiotic years (1950-60). He noted a decline in 
deaths due to infection (64% to 16%) and an increase in 
mortality caused by CHF (12% to 61 %) over these two peri¬ 
ods. The incidence of deaths attributed to major emboli 
(1 il% to 18$) and other causes (10? to 15?) had not 
changed significantly. 
In 1978 Garvey et al (24) reported a series of 154 
patients with 165 episodes of BE. Major embolic phenome¬ 
na occurred in 51? of patients with NVE and in 88? and 
65? of patients with early and late PVE respectively. 
CHF developed in 50? of patients with NVE and 34? with 
PVE. Persistent infection was documented in 5? of pa¬ 
tients with NVE and in 13? and 8? of patients respective¬ 
ly with early and late PVE. 
In 1970 Mandell (54) reported that major embolic 
episodes were "relatively common" in patients with EE, 
occuring 13 times in 10 patients during therapy. 
Moellering (60) found that 4 of 15 patients with EE de¬ 
veloped no significant complications, whereas 6 had major 
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emboli, 6 developed new murmurs consistent with valve 
destruction, and 3 developed CHF. None of the 15 pa¬ 
tients relapsed. 
The prognosis for patients with IE has improved 
since the pre-antibiotic and early antibiotic eras. An 
18 to 53% cure rate was reported in 1966 (47). A 75? 
overall survival rate for IE has been reported in recent 
years (79). Similarly, cure rates in EE have improved 
since the 1940's and 1950's. At that time, significantly 
higher mortality rates were reported for EE as compared 
to viridans endocarditis (47). In a 1968 review, 
Wessler and Avioli (105) reported overall mortality rates 
of IE of 10? to 25? whereas that for faecalis endo¬ 
carditis was 50?. 
"Cure" is variably defined, usually as survival for 
at least three to six months after completion of therapy 
without evidence of infection. In 1970 Mandell et al 
(53) cured 83? (17? mortality) of 36 patients treated 
with penicillin or ampicillin and streptomycin. None of 
these patients received valve replacements. Other re¬ 
ports (25,40,42,44) confirm a cure rate of over 80? in EE 
treated with penicillin and streptomycin, equivalent to 
that achieved in treating .£. viridans endocarditis (52). 
Serra et al (83) reported a 100? cure rate from 1972-76 
in 7 patients treated with ampicillin or penicillin and 

gentamicin. Significantly lower cure rates have been at¬ 
tributed to a patient population with an unusual number 
of serious underlying diseases. In a 10 year study of 
Group D streptococcal endocarditis at the MGH, 12 (92%) 
of 13 patients with S. bovis endocarditis survived whe¬ 
reas only 8 (57%) of 14 patients treated appropriately 
for EE survived (60). However, survival was not defined. 
It is now believed that, with surgical intervention 
as necessary, the cure rate of EE should approach that of 
non-enterococcal streptococcal endocarditis (85 to 90%) 
(41). 
PROGNOSTIC FACTORS 
A number of factors have long been known to corre¬ 
late with a complicated course and/or adverse outcome in 
BE. These include age, the organism, heart failure, the 
general condition of the patient, and the duration of in¬ 
fection before treatment (18). In addition, the site and 
extent of valvular involvement, presence of renal insuf¬ 
ficiency, and development of complications are important 
prognostic variables (47). 
The prognosis for patients treated for EE is im¬ 
proving. The fatality rate of patients with IE is hi¬ 
ghest in patients under age twenty and those over age 60 
(47). Higher mortality rates in elderly people may be 

due to the existence of other disease processes which can 
confuse the symptomatology of BE and result in a delay of 
diagnosis (47). Elderly patients are also more likely to 
have underlying diseases which may cause fatalities or 
predispose them to a more complicated course of IE. EE 
is known to occur in an older patient population than do 
other types of endocarditis (60). 
Congestive heart failure (CHF) has been identified 
as the single most important prognostic factor in BE. 
The development of CHF during therapy is associated with 
a high mortality rate (50-90$ with medical therapy alone 
(17). CHF is the major cause of death due to endocar¬ 
ditis in the antibiotic era, and has accounted for 61$ of 
deaths in one review (reviewed in 38). In another review 
(65), over 90$ of patients who died of IE had signiicant 
heart failure. The predictive value (the probability 
that a patient will die if he/she develops heart failure) 
approached 50$ (17). 
CHF in IE is most often a result of aortic and/or 
mitral valve insufficiency (reviewed in 38). CHF has 
been shown to develop significantly more frequently in 
the setting of AI than with MR (38). Risk factors for 
CHF in patients with endocarditis have also been identi¬ 
fied. Aortic versus mitral valve involvement, prosthetic 
versus native valve involvement, fistulae and prosthetic 
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valve dehiscence, the virulence of the organism, and the 
size of the vegetation all correlate with the development 
of CHF. In addition, there is evidence that endocarditis 
associated with new heart failure may carry a worse prog¬ 
nosis than disease which aggravates pre-existing failure 
(17). 
Other factors have been associated with a poor out¬ 
come. Karchmer et al (37) reported that invasion of the 
myocardium was associated with an increased mortality. 
Infections of native valves are usually confined to the 
valve leaflets, whereas prosthetic valve infections fre¬ 
quently extend into the valve seat and adjacent tissues. 
Infections extending beyond the valve leaflet may be re¬ 
flected in persistent fevers during therapy, a murmur of 
valvular insufficiency, atrioventricular conduction dis¬ 
turbances, and relapse of infection after therapy 
(37,38). Karchmer et al also reported that their pa¬ 
tients with prosthetic valve endocarditis (PVE), a new 
regurgitant murmur (indicative of valve dehiscence or 
dysfunction), moderate to severe CHF, and a non- 
streptococcal etiology, were associated, individually and 
especially together, with a higher mortality rate. 
Similar data has been reported for patients with native 
valve endocarditis (NVE) (37). 
Evaluation of cardiac valves through two- 
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dimensional and M-mode echocardiography may provide an¬ 
other prognostic indicator for patients with BE. A num¬ 
ber of investigators have suggested that patients whose 
infected valves have demonstrable vegetations are more 
likely to experience complications (CHF and major emboli) 
and require operative intervention (17,38,66). There is 
evidence that results of echocardiography correlate with 
the duration of illness as well as the outcome (66). 
However, the sensitivities and specificities of these 
correlations remain undefined and a prospective evalua¬ 
tion remains to be done. It has also been pointed out 
that a correlation between echocardiographically- demon¬ 
strated vegetations and an increased risk of complication 
or need for surgery does not preclude successful medical 
management (38). A weakness of echocardiography is that 
it does not differentiate between active and healed le¬ 
sions (reviewed in 28). 
The prognostic significance of the duration of ill¬ 
ness before treatment has received much attention. A re¬ 
view of BE in 1951 documented a significant correlation 
between duration of illness and mortality. At 6 month 
follow-up, 27$ of 357 patients with symptoms for less 
than 10 weeks before therapy had died , whereas 50$ of 
those with symptoms for 20 or more weeks were dead. This 
difference in mortality rate has been attributed to the 
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poor prognosis of heart failure which is more likely to 
develop in cases of longer duration. When controlled for 
the effect of heart failure, the duration of illness be¬ 
fore therapy correlated substantially less with outcome. 
Tompsett found no better results among those patients 
having symptoms for 1-2 months as opposed to 3-^ months 
before therapy (reviewed in 18). The average duration of 
illness before antibiotic therapy in an early review of 
33 cases of EE was 6 to 7 months (range 1 week to 3 ye¬ 
ars). In this study the duration of active disease be¬ 
fore treatment correlated with a poorer prognosis (25). 
Similar observations have been reported in the rab¬ 
bit model of EE (10). A longer delay before onset of 
therapy meant the infection would be more difficult to 
cure. Starting therapy 6 hours after the organism was 
injected into susceptible rabbits produced sterilization 
of many vegetations after 3 days, whereas delaying treat¬ 
ment for 1 to 3 days resulted in a much slower rate of 
sterilization. 
Malacoff et al and Phair et al have studied pa¬ 
tients with penicillin susceptible streptococcal endocar¬ 
ditis. They identified patients with illness for 3 
months or longer before institution of therapy as a group 
at high risk for relapse. Malacoff et al documented 2 
relapses in 13 patients (15$) with disease longer than 
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three months before therapy, and no relapses in 51 pa¬ 
tients with symptoms for less than or equal to three 
months prior to initiation of therapy. They suggest that 
single agent therapy for 23 days or less is not adequate 
treatment for patients with the longer duration of symp¬ 
toms. These patients may either require the addition of 
an aminoglycoside or a longer treatment period in order 
to achieve cure (51). In a recent review, Phair and Tan 
(66) conclude "duration of illness appears to be a highly 
relevant determinant of survival". 
Similarly, a recent article on penicillin sensitive 
streptococcal endocarditis (38) combined data from sever¬ 
al reviews and examined relapse rates in patients having 
symptoms longer than or less than 3 months, and receiving 
single antibiotic therapy or combined therapy for less 
than or equal to 21 days or greater than 21 days. The 
duration of disease was not significantly associated with 
the risk of relapse except in patients who received peni¬ 
cillin alone for equal to or less than 21 days. The au¬ 
thor concluded that therapy for 21 days or less is inade¬ 
quate therapy for longer duration disease, though prob¬ 
ably effective for disease of less than three months, 
thereby implying that the longer duration assigns a 
higher risk of relapse unless a longer treatment regimen 
is imposed. 
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PROSTHETIC VALVE ENDOCARDITIS 
Prosthetic cardiac valves predispose patients to 
the development of endocarditis, and to a complicated 
course of the disease with a high mortality rate. Early 
PVE occurs within two months of valve replacement and 
late PVE occurs two months or longer after valve replace¬ 
ment. The overall incidence of PVE varies from 0 to 9»5? 
with a mean of 2.3? (101). Early PVE has a much higher 
mortality rate (77?) than late PVE (42?) (109). 
Streptococci play a minor role in early prosthetic valve 
infections (about 7.5? of cases) in comparison with 
Staph, epidermidis (27?), Staph, aureus (19?), and gram 
negative bacilli (20?). Streptococcus is the number one 
etiology of late PVE (37? of cases) (101). 
Wilson et al (109) reported that PVE accounts for 
16? of cases of IE seen at the Mayo Clinic. As discussed 
above, PVE is associated with more complications and a 
higher mortality rate than is NVE. Four major types of 
complications occur in PVE: valve dysfunction (pros¬ 
thesis detachment or obstruction of the valve by a vege¬ 
tation), high grade a-v conduction abnormalities, annular 
infection and ring abscesses, and a high incidence of em¬ 
boli and ventricular and aortic aneurysms. 
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SURGERY 
Surgery is assuming an increasingly important role 
in the treatment of IE. The hemodynamic status of the 
patient has been the most important factor in determining 
the need for valve replacement (38,109). The degree of 
CHF has also been shown to be the single most important 
determinant of operative mortality (38). Recently, the 
indications for surgery have been extended in an attempt 
to anticipate complications rather than acting after 
their occurrence. 
Karchmer et al outlined features which indicate 
that the patient is unlikely to respond to medical thera¬ 
py. If two of three risk factors (non- streptococcal 
etiology, a new regurgitant murmur, moderate to severe 
CHF) are present or if myocardial invasion is evident, 
then early surgical intervention for native valve or PVE 
is recommended (38). Wilson et al (109) reviewed the 
outcome of patients with PVE and suggested three addi¬ 
tional indications for valve replacement: a malfunction¬ 
ing prosthesis, recurrent major emboli, and fungal PVE. 
Also, resistant infection- persistent bacteremia despite 
appropriate treatment for one week- is commonly consid¬ 
ered a reason to consider surgery (17,90). It appears 
that surgical intervention is more important in improving 
outcome in patients with PVE than in those with NVE (38). 
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In 1977 Saffle et al analysed three centers' exper¬ 
ience with PVE and reported a significantly lower mortal¬ 
ity rate (12 of 29, 41?) for patients treated with anti¬ 
biotics and valve replacement as compared with medically 
treated patients whose mortality rate was 62? (63 of 102 
cases) (reviewed in 38). Griffin et al (reviewed in 38) 
examined the outcome of a group of patients with a sa- 
tistically high mortality rate: patients with aortic in¬ 
sufficiency and moderate to severe CHF. Patients who 
were treated medically experienced an 88? mortality rate 
as compared to a 20? mortality rate among those treated 
with antibiotics and surgery. Other studies have con¬ 
firmed that the survival of patients with aortic insuffi¬ 
ciency and CHF is improved with aortic valve replacement 
(38). 
There are no randomly controlled prospective stu¬ 
dies comparing antibiotic therapy alone with antibiotic 
therapy plus valve replacement in complicated endocar¬ 
ditis. There are many variables which must be taken into 
consideration in making a clinical decision between these 
two approaches, and treatment is extremely individualised 
at present. The retrospective analyses are limited by 
hidden bias and selection criteria (71). In some reports 
only patients with significant myocardial reserve qualify 
for surgery, but most series indicate that the surgical 
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survival rates reflect the salvage of medical failures 
(17). 
Surgery in active endocarditis has become part of 
the trend toward more aggressive intervention in cases at 
high risk for high morbidity or mortality. Since surgery 
clearly plays a role in curing BE in selected patients, 
the question becomes when, rather than whether, to oper¬ 
ate. Surgery earlier in the course of endocarditis in 
high risk patients might save more lives since often the 
hemodynamic status of the pre-op patient (the major de¬ 
terminant of operative risk and prognosis) would be 
better than if surgery were delayed until later. 
Comparison of patients undergoing valve replacements be¬ 
fore versus after completion of a course of antibiotics 
would be more informative than analysing outcome of medi¬ 
cal versus surgical therapies (17). Recently, several 
centers have reported good results with early surgery 
(reviewed in 17). Karchmer and Stinson (38) reviewed re¬ 
sults of valve replacements in cases of active IE compli¬ 
cated by CHF alone or in combination with other major 
complications. In this group, medical management alone 
would result in an 80-100 mortality rate. They found the 
mortality rate was 37$ among 162 cases in one series and 
14-27$ among 200 patients from 7 other series. 
Early concern about poor operative outcome or high 
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rates of relapse after surgery for active endocarditis 
has been questioned by recent studies, especially in 
cases where death is almost certain with medical therapy 
alone (17,37,75,90). These studies have shown relapse 
rates of only 5? to "less than 10?" despite active infec¬ 
tion at the time of valve replacement. Delaying surgery 
to allow completion of antibiotic therapy may cause 
further complications and an increased mortality. 
The problem remains that some of the accepted indi¬ 
cations for surgical intervention are difficult to assess 
clinically (e.g., extravalvular intracardiac spread of in¬ 
fection). The decision about surgery and its timing must 
be individualised in each case. The key is to identify 
cases who are likely to do well on a medical regimen. 
Stinson (90) and Gregaratos (28) suggest that patients 
infected with a streptococcal pathogen (including entero¬ 
coccus) sensitive to bactericidal antibiotics and who 
have no major complications and do not have prosthetic 
valves, fit into this category. Stinson (90) emphasized 
that surgery now assumes a role in removing the infective 
lesion itself as well as in repairing mechanical dysfunc¬ 
tion. Clearly, surgical management of IE should be con¬ 
sidered at any time during the course of complicated IE, 
preferably as soon as features indicating a high risk of 
complications are identified. 
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PROPHYLAXIS 
Antibiotic prophylaxis is indicated as an attempt 
to prevent the development of BE among patients with con¬ 
genital and valvular heart disease undergoing certain in¬ 
vasive procedures. Prophylaxis has become a well- 
accepted practice despite a paucity of prospective con¬ 
trolled studies. However, results of several studies in 
animals have provided a foundation for concepts of pro¬ 
phylaxis against IE (reviewed in 43). For example, Du- 
rack et al (19) studied rabbits with j§. faecalis endo¬ 
carditis. Their data suggested that treatment with ampi- 
cillin or vancomycin in combination with an aminoglyco¬ 
side might provide adequate prophylaxis against endocar¬ 
ditis caused by streptomycin-sensitive S. faecalis. 
Only certain procedures associated with a substan¬ 
tial risk of streptococcal bacteremia, including dental 
surgery, tonsillectomy, adenoidectomy, bronchoscopy, and 
urologic procedures, require antibiotic prophylaxis. 
Prophylaxis is used only for the immediate perioperative 
period (about 48 hours) as prolonged use of broad spec¬ 
trum agents may predispose to superinfection with unusual 
or highly resistant organisms (36). 
Specific recommendations vary from author to au¬ 
thor. The AHA recommendations (36) include a standard 
58 

program (oral and parenteral penicillin) for patients un¬ 
dergoing dental procedures or upper respiratory tract 
surgery. This regimen does not adequately cover entero¬ 
coccus. The regimens for patients at high risk for endo¬ 
carditis who undergo gu and gi procedures (where entero¬ 
coccus is more commonly found) or dental surgery do in¬ 
clude antibiotics bactericidal for enterococci (penicil¬ 
lin and streptomycin or gentamicin). 
Patients undergoing open heart surgery, especially 
with placement of a prosthesis, are at high risk for de¬ 
veloping IE postoperatively. Early post-op endocarditis 
is most often due to Staph. aureus or Staph. 
epidermidis. so antibiotic prophylaxis is directed pri¬ 
marily against these bacteria and usually consists of a 
brief period of a cephalosporin or a penicillinase- 
resistant penicillin (36,43). Enterococcus, a relatively 
rare but documented cause of endocarditis complicating 
open heart surgery (65) is not adequately covered by 
these regimens. 
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METHODS 
PATIENT POPULATION 
Patients records were obtained by a review of the 
discharge diagnoses of the hospitals medical records de¬ 
partments, the blood culture records from the clinical 
microbiology laboratory, and the consult records of the 
Infectious Diseases Section of the Department of Medi¬ 
cine. At the main Yale University hospital, Yale-New Ha¬ 
ven Hospital (YNHH), and the Yale affiliated hospital, 
St. Raphael's Hospital (HSR), all available records be¬ 
aring a discharge diagnosis of BE between October, 1970 
and March, 1982 (YNHH) or between January, 1972 and De¬ 
cember, 1981 (HSR) were examined. Of 22^ charts so coded 
at YNHH during this interval, 173 were available for re¬ 
view. At the HSR, where this discharge diagnosis was 
coded 78 times, 76 charts were examined. 
Blood culture result books were reviewed at the 
West Haven Veterans Administration Hospital (WHVAH), a 
Yale University hospital, from January, 1970 through 
April, 1982 and at the YNHH from January, 1971 to Febru- 
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ary, 1982. The names of patients with two or more blood 
cultures positive for enterococci were recorded. The 
charts of these patients (48 available of 66 requested at 
the YNHH and 36 of 48 at the WHVAH) were also examined. 
YNHH Infectious Diseases consult records from 1967 to 
1982 were reviewed for patients with EE. In addition, 3 
patients' records from St. Mary's Hospital, a Yale affi¬ 
liated hospital, were contributed to the study by the 
Chief of Infectious Disease at that hospital. 
Of these available records, only patients with EE 
who met one of the following two sets of criteria, were 
included in the present study: 
I. (1) Two or more blood cultures positive for en¬ 
terococcus. 
OR 
A valve culture positive for enterococcus 
(2) A cardiac murmur present on admission or devel¬ 
oping during the 
course of the disease 
(3) A clinical syndrome (history, physical findings, 
and symptoms) 
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consistent with IE 
In addition, cases received the diagnosis of EE and 
were included in the study if they fulfilled criteria as 
follows: 
II. (1) 1 blood culture positive for an entero¬ 
coccus while on antibiotic 
treatment 
OR 
No blood cultures positive while on 2-antibiotic 
therapy, but 
peritoneal fluid repeatedly positive for entero¬ 
coccus 
(2) A cardiac murmur present 
(3) A clinical syndrome consistent with IE 
Review of the records at these four Yale hospitals 
yielded 42 episodes of EE in 37 patients. Four patients 
suffered 5 relapses. 
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BACTERIOLOGIC TESTING 
Once a streptococcal isolate was identified as 
group D through testing with group antiserum and the 
bile-esculin test, a standard combination of physiologic 
characteristics was used to differentiate ncn- 
enterococcal group D streptococci from enterococci (e.g., 
6.5? NaCl tolerance test) and to speciate the enterococ¬ 
ci. (see tables for methods used) 
MIC determinations were made using the SENSITITRE 
micro-plating method. (Gibco diagnostic labs). 
DATA ABSTRACTION 
A careful review of the hospital charts of these k2 
cases yielded the study data. Each patient was charac¬ 
terized as to physical description (age, sex, weight, 
etc.), pertinent past medical history, presenting symp¬ 
toms, physical findings, and laboratory abnormalities and 
echocardiography and catheterization results. Evidence 
for valvular heart disease included a history of rheumat¬ 
ic fever or rheumatic heart disease, prior IE, the pres¬ 
ence of a prosthetic valve, or a heart murmur noted on at 
least 2 previous occasions. The site of valvular in- 
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volvement was determined by the presence of aortic or mi¬ 
tral regurgitation on physical examination, or when echo¬ 
cardiography, surgery, or autopsy demonstrated vegeta¬ 
tions. 
Information on the source and probable mechanism of 
infection (i.e. TURP, uti, etc) was included. The iden¬ 
tity of the causative organism and its disk sensitivity 
and MIC and MBC, where available , were recorded. 
Details of treatment were abstracted, including antibiot¬ 
ics (dose, route, and duration), aminoglycoside serum 
levels and SIC and SBC levels, when available, and side 
effects of treatment. Also noted were the length of fol¬ 
low-up, the timing and indications for valve replacement, 
any complications of the disease process, pathology find¬ 
ings, and outcome (death, cure, relapse). 
Data was analysed to assess the prognostic signifi¬ 
cance of various factors for this patient population. 
The parameters which we considered most significant in 
evaluating prognosis and outcome in this disease were: 
(1) development or worsening of CHF 
(2) requirement of valve replacement 
(3) ocurrence of major embolic phenomena 

(4) persistence of fever without other explanation 
(5) relapse 
(6) death 
Major embolic phenomena were defined as documented 
or strongly suspected emboli other than microemboli in 
the subcutaneous tissues. Included in this term were my¬ 
cotic aneurysms, hemorrhages within the central nervous 
system, and renal failure not attributed to drug toxici¬ 
ty. Persistent fever was defined as a temperature great¬ 
er than 100.5 degrees F lasting one week or longer after 
the commencement of antibiotic treatment or the recur¬ 
rence of fever on therapy after the patient had been afe¬ 
brile for one week. Only cases judged unrelated to drug 
hypersensitivity were included. Relapse was defined as a 
patient requiring re-treatment for the same species of EE 
within 6 months of completion of the initial treatment. 
Any patient who died on therapy or who died of cardiac 
causes within 6 months of completion of therapy was 
counted as a mortality in this study. 
Follow-up of patients after discharge was done by 
chart review and/or questioning of the patient's physi¬ 
cian and review of his or her records. Follow-up was 
terminated at the end of 1982. 
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ASSESSMENT OF THERAPY 
Patients were divided into groups for analysis of 
outcomes following treatment with different regimens. In 
addressing the three issues stated in the introduction, 
patients were assigned to three sets of groups. First. 
those patients who received a penicillin or vancomycin 
and an aminoglycoside (the recommended therapy) were 
compared to patients who received alternative therapies 
(cephalothin, tetracycline, cefamandole, erythromycin, 
sometimes in combination with ampicillin or penicillin, 
or surgery alone). These two groups were also analysed 
after exclusion of patients who underwent valve replace¬ 
ment surgery as part of the treatment. Second, patients 
who received four or more weeks of an aminoglycoside were 
compared to those who received less than weeks but at 
least 12 days of an aminoglycoside and at least M weeks 
of treatment with a cell wall active agent (penicillin, 
ampicillin, or vancomycin). The outcomes of these two 
groups of patients were also analysed after exclusion of 
all patients who (1) had prosthetic valve infections or 
(2) had valve surgery. Third, patients whose treatment 
for EE included valve replacement were compared to those 
66 

treated only with antibiotics. 
Data were analysed to detect any differences be¬ 
tween each two groups being compared with regard to fac¬ 
tors reported to influence outcome in IE. The rates of 
complications and death for patients in each set of 
groups were then analysed to determine whether for these 
patients (1) standard therapy is significantly better 
than alternative therapies, (2) k or more weeks of amino¬ 
glycoside therapy improves the prognosis in comparison to 
those who receive less than four weeks, and (3) surgery 
in combination with antibiotic therapy significantly im¬ 
proves outcome over those who receive antibiotic therapy 
alone. 
DATA ANALYSIS 
Frequencies and means were calculated for 37 pa¬ 
tients. Occasionally, data for all ^12 episodes of EE or 
data for the 33 patients who did not relapse are present¬ 
ed. This is noted in the tables. The number of patients 
in whom the observation was made is given in all cases. 
Data was analysed using the t-test and the Fisher 
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Exact Test where appropriate. A 5% level of significance 
was used in interpreting the statistics. 
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RESULTS 
(A) INCIDENCE 
All available charts of patients with a discharge 
diagnosis of BE were reviewed at two hospitals (YNHH and 
HSR). Streptococci accounted for just under 50? of cases 
at both hospitals (Table 1). At YNHH, which is a refer¬ 
ral center, the proportion of endocarditis cases with en- 
terococcal etiologies was 17?, whereas at HSR, a communi¬ 
ty hospital, the proportion was 8?. A large number of 
endocarditis cases seen at YNHH are referred from other 
hospitals for further diagnostic work-up and for surgical 
intervention. 
(B) SEX AND RACE 
Of the 37 patients in this study, 27 (73?) were 
male and 10 (27?) were female. The male to female ratio 
was 2.7 to 1 (Table 2). The male predominance persisted 
after omitting the 3 male WHVAH patients (corrected ratio 
is 2.4 to 1). Table 2 also shows the sex distribution by 
anatomic site of infection. 13 of 15 cases (87?) of na¬ 
tive aortic valve endocarditis and 6 of 8 cases (75?) of 
prosthetic aortic valve endocarditis occurred in male pa- 
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tients. The male predominance was less marked among pa¬ 
tients with mitral valve infections: 5 of 10 patients 
with native valve endocarditis and 3 of 5 patients with 
prosthetic valve endocarditis. All patients in this 
study were Caucasian even though there is a large black 
and hispanic population in New Haven. 
(C) AGE 
The mean age of patients was 60 years (median 61 
years) with a range from 0.25 to 84 years (Table 3)- 
Nineteen (51?) of the 37 patients were over age 60. 
There was no statistical difference between the median 
ages of male (60 years) and female (59 years) patients in 
this study. 
(D) VALVE INVOLVEMENT 
Infections of the aortic valve occurred in 19 pa¬ 
tients (51?) and 11 patients (30?) had mitral valve in¬ 
fections (Table 9). In four patients both valves were 
involved. The involved valve(s) could not be determined 
in 3 cases. Prosthetic valve infections developed in 12 
patients (32?). Of these, 7 (58?) had prosthetic aortic 
valves, 4 (33?) prosthetic mitral valves, and one patient 
had both aortic and mitral valve prostheses. Five of the 
12 patients with PVE (42?) developed endocarditis within 
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2 months of valve replacement. These early prosthetic 
valve endocarditis cases occurred a mean of 2.H weeks af¬ 
ter surgery. 
(E) UNDERLYING ILLNESS 
An underlying disease was present in the majority 
(70?) of the patients (Table *0 . There was evidence of 
pre-existing valvular heart disease in 19 (51$) patients. 
Eight (22$) patients had a history of rheumatic fever or 
rheumatic heart disease. Six of the 8 patients were wom¬ 
en. 
Six patients (16$) had a heart murmur documented on 
at least 2 occasions without receiving a specific diag¬ 
nosis. Two patients (6$) had a previous episode of (non- 
enterococcal) endocarditis. Twelve patients (32$) had 
undergone cardiac valve replacement surgery. Seven of 
the 12 patients had a Starr-Edwards prosthesis, 1 had a 
Bjork-Shiley, and 2 had a St Jude valve. None of the pa¬ 
tients had porcine valves. 
Non-valvular heart disease was identified in 12 pa¬ 
tients (32$). Six patients had coronary artery disease; 
2 of these had undergone coronary artery bypass surgery. 
Eight patients had a prior history of CHF and one patient 
(the only child) had non-valvular congenital heart di- 
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sease (ASD and VSD). 
A few patients had a history of other chronic 
illnesses: diabetes mellitus (2), renal failure (2), im¬ 
munosuppression (2), alcoholic liver disease (1). A sig¬ 
nificant proportion of patients with IE admitted to New 
Haven hospitals give a history of iv drug abuse. Yet 
none of the patients in this study gave such a history. 
(F) SOURCE OF INFECTION 
Nineteen of 37 patients (51%) had a history of a 
surgical procedure- cardiac, dental, genitourinary (gu), 
or gastrointestinal (gi) - between 1 to 10 weeks prior to 
the development of symptoms (mean 18 days) (Table 5). 
These invasive procedures were judged to provide the por¬ 
tal of entry for enterococci. Five of these patients re¬ 
ceived po or parenteral prophylactic therapy (penicillin, 
ampicillin, cephalosporin, and/or aminoglycoside). The 
probable sources of the enterococcal bacteremias are out¬ 
lined in Table 6. A source was not apparent in 5 pa¬ 
tients (1 ) and no work-up was done. In 2 patients a gi 
work-up was done and was negative and no other source was 
evident. No patients gave a history of parenteral drug 
abuse. A probable portal of entry was identified in 30 
(81?) of patients. 
A probable gu source (urinary tract disease or gu 
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instrumentation) was found in 8 patients (22%). One pa¬ 
tient had a urethral stricture and one had prostatic hy¬ 
pertrophy wit prostatism. In 6 patients a urinary tract 
infection (uti) with enterococcus was documented during 
the admission for EE. In 2 patients (one with nephropex¬ 
ies and recurrent uti's) the uti's were the most likely 
source of the bacteremias. Gu instrumentation or surgery 
preceeded infection in 4 patients (11%). These included: 
TURP, suprapubic prostatectomy, cystoscopy, and hysterec¬ 
tomy. Gi disease or gi procedures were the probable 
source of infection in 9 patients (24%). Five patients 
(1M%) were found to have a gi polyp or gi cancer. 
In 4 patients (11%) dental procedures provided the 
probable portal of entry for enterococcus. Six patients 
(16%) had undergone recent catheterization or cardiac 
surgery (1 cath, 4 valve replacements, and 1 valve re¬ 
placement combined with a coronary artery bypass graft 
(CABG)). At least 3 of these patients received perioper¬ 
ative prophylaxis with a cephalosporin. 
(G) PRESENTING SYMPTOMS 
Presenting symptoms for all patients are listed in 
Table 7. Fever occurred in 28 (76%) of patients. 26 
(70%) of patients complained of fatigue, weakness, or ma¬ 
laise. New or worsening symptoms of CHF occurred in 14 
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patients or 38$ of the group. Neurological symptoms (di¬ 
sorientation) occurred in 2 patients, one with a cerebro¬ 
vascular accident. 
(H) DURATION OF SYMPTOMS 
The mean length of time between onset of symptoms 
attributed to endocarditis and the diagnosis and treat¬ 
ment of the disease was 62 days (Table 8). Data was 
available for 32 of 37 first episodes of EE. 
Patients with PVE had a significantly shorter dura¬ 
tion of symptoms (mean 21 days) prior to treatment than 
patients with NVE (mean 79 days) (p < .002). The pa¬ 
tients with prosthetic valves included 5 cases of early 
PVE. Patients with aortic valve infections presented 
with a shorter duration of symptoms (57 days) than those 
with mitral valve endocarditis (69 days), though this 
difference was not significant. Patients with bivalvular 
infection had a longer mean duration of symptoms (75 
days) than patients with' univalvular involvement, but 
this was not statistically different (p < 0.3)* 
(I) PHYSICAL FINDINGS 
Table 9 summarizes the presenting physical findings 
in these 37 patients. Heart murmurs were heard in 35 
(95$) of 37 patients on presentation. Fever (temperature 
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> 100.5 degrees F) was present in 76? of patients. 
"Classic" peripheral signs (splinter hemorrhages, Osier's 
nodes, Roth's spots, petechiae, or Janeway's lesions) 
were present in 28 (76?) patients (Table 9)* 
Splenomegaly was present on examination of 12 (32?) pa¬ 
tients. 
(J) LABORATORY STUDIES 
The presenting laboratory data is shown in Table 
10. The most common abnormal laboratory finding was an 
elevated erythrocyte sedimentation rate (ESR) which was 
noted in 29 of 29 patients (100?) in which this test was 
obtained. Eighty-six percent of the patients were anem¬ 
ic. Serologic tests for rheumatoid factor were positive 
for 12 of 22 patients (55?). The mean hemoglobin was 
11.0. A white blood cell count (wbc) greater than 10,000 
was found in 18 of 37 patients (49?); the mean wbc was 
9.9. Complement levels were abnormal in 9 of 21 patients 
(43?). Pyuria, proteinuria, and hematuria were found in 
58, 44, and 35 percent, respectively, of patients who 
were tested. Ten of 24 echocardiograms (42?) were inter¬ 
preted as showing signs of a vegetation on either the 
aortic valve (7 patients) or the mitral valve (3 pa¬ 
tients) . 
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(K) MICROBIOLOGY 
The mean number of blood cultures positive for en¬ 
terococci was 4.3 of a mean total of 5 cultures done. 
One patient with the symptoms and signs of endocarditis 
had repeatedly negative blood cultures at a neighboring 
hospital. She was transferred to YNHH and underwent aor¬ 
tic valve replacement for aortic stenosis and regurgita¬ 
tion. The native aortic valve grew enterococci. 3 pa¬ 
tients, all with prosthetic valves and with the signs and 
symptoms of endocarditis, were diagnosed as having EE 
when one blood culture grew enterococci during current or 
recent antibiotic coverage. One patient on peritoneal 
dialysis had negative blood cultures on several occa¬ 
sions, but his peritoneal fluid consistently grew entero¬ 
cocci and his physical examination was remarkable for the 
stigmata of endocarditis. The remaining 37 episodes of 
EE in this study were all diagnosed on the basis of two 
or more blood cultures positive for enterococci. 
The enterococci isolated from cultures in these 42 
episodes of endocarditis were only occasionally speciat- 
ed. One patient's cultures grew faecium. This pa¬ 
tient relapsed three times and grew .£. faecium each 
time. Two patients' cultures were identified as 
faecalis and two patients were infected with j§. durans. 
One patient's cultures grew avium; the remaining cul- 
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tures were characterized simply as enterococci. 
Minimum inhibitory concentration (MIC) and/or mini¬ 
mum bactericidal concentration (MBC) determinations were 
done for 26 of 42 organisms isolated. In all cases the 
MIC to penicillin was at least 0.5 mcg/ml. Table 11A 
shows the MIC's and MBC’s to commonly used antibiotics 
for the organisms which were not responsible for bacteri- 
ologic relapses. The MIC’s and MBC’s for enterococci 
isolated from patients who relapsed are shown in Table 
11B. The median MIC to penicillin was higher for the re¬ 
lapse organisms (4.0) than for the non-relapse organisms 
(3*1) but the difference was not statistically signifi¬ 
cant. The median MBC was slightly higher for the non¬ 
relapsing organisms. None of the enterococci isolated 
demonstrated high level resistance to streptomycin. 
(L) FOLLOW-UP 
One patient died of an unrelated cause just after 
the treatment period. One patient was treated, then re¬ 
treated for a relapse of EE and lost to follow-up. These 
patients are excluded from all analyses related to pa¬ 
tients* outcomes. The remaining 35 patients (40 episodes 
of endocarditis) were followed for at least six months or 
until they died of their disease. The 26 patients who 
survived were followed for a mean of 43.5 months. 
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Twenty-one patients were followed for more than one year. 
(M) TREATMENTS 
Details of the antibiotic treatments which each pa¬ 
tient received are presented in Table 12. One patient 
whose diagnosis of EE was made only through culture of 
her aortic valve after valve replacement received no an¬ 
tibiotic therapy in addition to the surgery. The remain¬ 
ing Ml episodes of EE were treated with a course of anti¬ 
biotics. 
Patients were assigned to 3 sets of treatment 
groups on the basis of type and duration of therapy re¬ 
ceived. These grouDS and the criteria for assignment of 
patients are shown in Table 13. Patients with endocar¬ 
ditis who relapse are more likely to have an unfavorable 
outcome from subsequent treatment courses. In these ana¬ 
lyses the 5 patients who had relapsed were excluded, per¬ 
mitting comparison of the first treatment courses. In 
addition, the 2 patients described above were excluded 
because of insufficient data about the final outcome of 
their EE. (One of these 2 was also a relapse case). 
Therefore, 36 patients were available for analysis. 
Of the 36 patients for whom outcome data was avail¬ 
able, 26 (72$) received treatment with a cell wall active 
agent (ampicillin, penicillin, or vancomycin) and an ami- 
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noglycoside. The minimum and mean duration of aminogly¬ 
coside treatment were 12 days and 34 days respectively. 
For these patients the total duration of antibiotic 
treatment was at least 26 days. Only antibiotics admin¬ 
istered for greater than 2 days were included. 
Ampicillin was the cell wall active agent administered to 
6 of the 26 patients (23?) whereas penicillin was select¬ 
ed for 13 (50?) of the treatment regimens. Ampicillin 
and penicillin were both used in four cases (11?) and 
vancomycin was used alone or in combination with ampicil¬ 
lin or penicillin in 3 cases (12?). 
A wide range of doses of antibiotics were administ¬ 
ered. The doses were less standardized in the earlier 
years of the study. The average daily doses (excluding 
the one child in this study) for antibiotics were: 
penicillin 4 to 44 mu (mean 21 mu), ampicillin 6 to 12 
grams (mean 9 grams), and vancomycin 0.4 to 2 grams (mean 
1.5 grams). With very few exceptions, all drugs were ad¬ 
ministered intravenously except streptomycin which was 
given intramuscularly. 
Eight of the 36 patients (22?) were given "non¬ 
standard" treatments which did not include either (1) an 
aminoglycoside administered concurrently with penicillin, 
ampicillin, or vancomycin, (2) vancomycin, or (3) ampi¬ 
cillin for more than 8 days. These alternative regimens 
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included: surgery alone (one patient), cephalothin, tet¬ 
racycline, cefamandole, penicillin, ampicillin, gentami¬ 
cin, streptomycin, and erythromycin. These 8 patients 
(group IB) are compared with the 26 patients (group IA) 
who received "standard" therapy. 
Two patients were treated with antibiotics which 
can neither be considered "standard" recommended thera¬ 
pies nor untested "alternative" treatments. One patient 
received 42 days of vancomycin and the other received 10 
days of ampicillin and 22 days of vancomycin. These pa¬ 
tients were both cured of their endocarditis. They are, 
however, excluded from assignment to the treatment groups 
(which separate patients according to "standard" versus 
"alternative" therapies). 
Ten of the 26 patients (38%) receiving "standard" 
therapy received an aminoglycoside for less than 4 weeks 
(mean = 23 days). Sixteen patients (62%) received at 
least 4 weeks of aminoglycoside therapy (mean = 40 days). 
These two groups of patients form treatment groups IIA 
and IIB. 
Eleven patients (30%) received a valve replacement 
as complete or partial treatment for their endocarditis. 
Eight of these patients received one of the "standard" 
antibiotic therapies referred to above in addition to the 
surgery. In treatment groups III these 8 patients are 
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compared to 18 patients who received "standard" therapies 
without valve replacements. 
The majority of patients who underwent surgery re¬ 
ceived aortic valve replacements (7 of 11 or 6*4?) while 2 
patients each (18?) received mitral or both mitral and 
aortic prostheses. A higher ratio of patients with aor¬ 
tic valve disease (7 of 20 or 35$) than with mitral valve 
infections (2 of 10 or 20$) required valve replacements 
but the difference is not statistically significant. 
Six of the operations were semi-emergent. These 
valve replacements were done without completion of a full 
coure of antibiotic therapy. The mean duration of anti¬ 
biotic therapy prior to surgery was 16 days. The indica¬ 
tions for surgical intervention in these patients were: 
persistent bacteremia (1 patient), recurrent emboli (1 
patient), a sudden deterioration in mental status (1 pa¬ 
tient), a change in mental status following a cardiac ar¬ 
rest (1 patient), and progressive mitral and aortic re¬ 
gurgitation with neurologic deterioration (1 patient). 
One patient received a valve replacement for worsening 
aortic stenosis and regurgitation prior to the definitive 
diagnosis of EE (which was made on the basis of the valve 
culture). Four patients required valve replacements 
within 3 months of completion of a course of antibiotic 
treatment. The indications for these operations 
81 

included: recurrent emboli and new CHF (1 patient) and 
progressive mitral and/or aortic regurgitation (3 pa¬ 
tients) . 
(N) THERAPIES FOR PENICILLIN ALLERGIC PATIENTS 
Six patients in this study had a prior history of 
an allergy to penicillin. Most of the patients described 
the development of a rash on penicillin. One patient was 
found to have a positive reaction to the major determi¬ 
nant of penicillin on skin testing. Desensitization was 
successfully accomplished in one patient who developed a 
rash on vancomycin therapy. She was then treated with 
penicillin for 18 days without further allergic reac¬ 
tions. One patient recieved M2 days of vancomycin and 
one patient received vancomycin alone or with gentamicin 
for a total of 36 days. Two patients were given a course 
of cephalothin (either alone or in combination with 
streptomycin) without any evidence of an allergic reac¬ 
tion. Finally, one patient received a M6 day course of 
po and iv erythromycin. This patient died of a cerebral 
embolus one week after discharge. The other 5 patients 
were all cured of their disease. 
(O) MONITORING THERAPY 
Efficacy of antibiotic therapy was assessed with 
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serum inhibitory concentration (SIC) and/or serum bacter¬ 
icidal (SBC) titers in 65% of the patients. However, 
many patients had multiple changes in their antibiotic 
regimens and the timing of the titers with respect to the 
dosing intervals varied. Therefore no statement can be 
made about SIC and SBC titers as a parameter for monitor¬ 
ing therapy. 
The erythrocyte sedimentation rate and rheumatoid 
factor were repeated in so few patients that these tests 
cannot be assessed as indicators of successful therapy. 
(P) COMPLICATIONS OF THERAPY 
Overall, 24 of 41 patients (58%) treated with anti¬ 
biotics developed side effects. Renal complications at¬ 
tributed to aminoglycosides were the most common. 
Seventeen patients, including 12 who received a cell wall 
active agent in combination with an aminoglycoside, 
showed no signs of toxicity. The significant non-renal 
reactions included vestibular and/or hearing impairment 
due to streptomycin (31% of those receiving streptomycin) 
and fever or rash attributable to cell wall active agents 
(Table 14). 
The mean duration of aminoglycoside treatment was 
33 days. Fourteen (40%) of the 35 patients who were 
treated with an aminoglycoside developed signs of renal 
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toxicity. The duration of aminoglycoside therapy in the 
group with renal compromise was 12 to 40 days with a mean 
of 27 days. Twenty-one patients tolerated the aminogly¬ 
cosides without signs of renal problems. The duration of 
treatment in these patients was 5 to 64 days with a mean 
of 36 days. There was a significantly longer duration of 
aminoglycoside treatment in the group without renal toxi¬ 
city (p=0.04) because a rising creatinine often led to 
discontinuing aminoglycoside treatment. Patients who to¬ 
lerated aminoglycoside therapy well were more likely to 
receive a 6 week course of therapy. 
Table 14 shows the rates of renal complications as¬ 
sociated with different aminoglycosides and the maximum 
creatinine as well as the duration of renal dysfunction. 
Although the numbers are small, patients who received 
gentamicin were more likely to have renal complications 
than those who received streptomycin or tobramycin. 
Gentamicin caused renal dysfunction in 30? of patients in 
contrast to a 13? rate of renal complications in those 
who received other aminoglycosides. One of two patients 
who received vancomycin in combination with an aminogly¬ 
coside (gentamicin) developed signs of renal impairment. 
(Q) MORBIDITY AND MORTALITY 
Table 15 describes the major complications of EE 
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(including death) seen in 40 episodes of the disease. 
Disease-related morbidity and mortality were included for 
the period from onset of symptoms to 6 months after ter¬ 
mination of antibiotic therapy. Two patients are exclud¬ 
ed, as previously described, due to incomplete follow-up. 
One or more complications occurred in 32 (80$) of 
40 episodes of EE. Eight patients had an uneventful 
course. Sixty-nine percent of 13 patients with native 
aortic valve endocarditis and 88$ of 8 patients with na¬ 
tive mitral valve endocarditis had one or more complica¬ 
tions related to their disease. These rates are not sig¬ 
nificantly different from the rates of complications in 
patients with PVE (10 of 13 patients or 77$). Three of 3 
patients with aortic and mitral valve involvement had 
complications but this was not statistically different 
from the rates of complications with single valve di¬ 
sease . 
Ten patients (25$) developed new CHF or had a 
severe deterioration in a previously stable pattern of 
CHF. One patient (13$) with native mitral valve endocar¬ 
ditis, 3 patients (23$) with native aortic valve endocar¬ 
ditis, and 3 patients (23$) with PVE developed CHF. 
These rates of CHF do not differ significantly. The per¬ 
centages of patients who suffered embolic phenomena, per¬ 
sistent fever, relapse, or death were not significantly 
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different for those with aortic or mitral valve disease. 
Morbidity and mortality rates for patients with NVE 
and PVE are presented in Table 16. The 11 patients with 
PVE had higher rates of embolic episodes and death than 
patients with NVE, but these differences were not sta¬ 
tistically significant. A smaller percentage of patients 
with early PVE were cured (JJ0$) than were cured of NVE 
(76$). Similarly, data from cases with early PVE demon¬ 
strated higher rates of embolic episodes, CHF, relapse, 
and death. The numbers are small and these differences 
were not statistically significant. 
Seven patients in this study developed new signifi¬ 
cant conduction abnormalities (atrio-ventricular block, 
right bundle branch block, or left anterior hemiblock in 
any combination) and/or had findings of myocardial pa¬ 
thology at surgery. The myocardial pathology included a 
torn or perforated valve cusp, or an aneurysm or abscess 
of the sinus of valsalva). Four of these patients were 
eventually cured. Pathologic examination of valves was 
performed in 13 cases (2 autopsies and 11 valve replace¬ 
ment operations). Nine of the 13 valves (69$) demon¬ 
strated gross vegetations; one of these vegetations 
yielded gram positive cocci on gram stain. Four vegeta¬ 
tions which were stained and cultured showed no signs of 
micro-organisms. One valve from an untreated patient 
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grew enterococci. 
Persistent fever complicated 11 cases (28$). In 
one case an abscess of the sinus of valsalva was docu¬ 
mented. In 7 of these patients embolic episodes were ei¬ 
ther documented (a renal artery embolus and 2 patients 
with cns bleeds) or strongly suspected (a pulmonary ar¬ 
tery embolus and 3 patients with microemboli to the cns). 
In two cases the source of fever was unclear. None of 
the patients who relapsed had persistent fevers on thera¬ 
py- 
Nine patients (23$) died of causes related to endo¬ 
carditis. Three additional patients died of unrelated 
causes (acute aspiration, cancer of the urethra and gi 
bleeding, and intestinal obstruction due to colon cancer. 
In two of the three cases death occurred months or years 
after a cure of EE was documented. 
Five patients died of cardiac causes: cardiac ar¬ 
rest (3 patients), pulmonary edema and ventricular ar¬ 
rhythmias (one patient), valve dehiscence (one patient). 
Three patients died of neurologic complications presum¬ 
ably related to emboli. One patient died of multi-organ 
failure following an aortic valve replacement. 
Three patients died during treatment. The 6 others 
died from one week to 6 months following completion of 
therapy (mean = 10 weeks). The mean age at diagnosis of 
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those who ultimately died from their disease was 66 years 
(median 61 years), not statistically different from the 
mean age of those who survived. Table 17 shows the age 
distribution and age-related mortality rates in this 
study. 
One of 11 patients (14$) who underwent surgery died 
(probably a surgery- related death) and 10 of 11 (91$) 
were cured. This compares favorably with the overall 
cure rate (67$) and mortality rate (22$). Six of the 7 
patients who underwent surgery before completion of a 
course of antibiotic therapy were cured. All four of the 
patients who completed a four week course of antibiotics 
were cured. Only one patient was documented to have ac¬ 
tive endocarditis at the time of surgery; she was cured 
with surgery alone. 
(R) COMPARISON OF TREATMENT GROUPS 
-I- The data was analyzed to determine any underly¬ 
ing differences among the groups which might affect out¬ 
come (Table 18A). The comparison of treatment groups IA 
and IB shows very similar numbers or frequencies in each 
group with respect to age, anatomical sites of involve¬ 
ment, underlying illnesses, presenting symptoms, and the 
decision to operate. The mean duration of symptoms was 
less in group B than in group A but the difference was 
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not significant (43 days vs. 71 days, p=0.095). 
However, the duration of therapy for EE did differ signi¬ 
ficantly between the two groups. Four patients (16%) in 
group A as opposed to 7 patients (88%) in group B re¬ 
ceived less than 21 days of antibiotic therapy. 
-II- Patients who received the "standard" regimens 
tended to be older (59 years vs. 50 years), have mitral 
valve rather than aortic valve involvement, and a shorter 
duration of symptoms (59 days vs. 93 days) as compared 
to patients who received "alternative" treatments. These 
differences were not statistically significant. However, 
all patients with PVE who received aminoglycoside therapy 
were in group IIA (p=0.009). Patients in group A had a 
significantly more frequent history of prior valvular 
heart disease than patients in group B (p=0.04l). The 
percentages of patients in each group who received spe¬ 
cific antibiotics (ampicillin, penicillin, streptomycin, 
gentamicin) were similar. 
-Ill- Comparison of treatment groups IIIA and IIIB 
demonstrates slight differences in the percentages of pa¬ 
tients with various anatomical sites of infection and 
underlying conditions. These groups did have a signifi¬ 
cantly different mean duration of symptoms prior to diag¬ 
nosis (51 days in A vs. 115 days in B, p=.006). This is 
consistent with the fact that all patients with PVE (who 
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had a shorter duration of illness) received at least H 
weeks of aminoglycoside therapy. 
(S) COMPARISON OF OUTCOME IN TREATMENT CROUPS 
In this study 67$ of patients were cured overall. 
Seventy-six percent of those who received penicillin, am- 
picillin, or vancomycin in combination with an aminogly¬ 
coside were cured. Eighty-one percent of patients devel¬ 
oped one or more major complications, including 11$ who 
relapsed and 8 (22$) who died. 
The incidence of major complications of EE and the 
rates of cure are summarized by treatment group in Tables 
19A, B, and C. In addition to the analyses described 
above, groups I and II were re-analysed after exclusion 
of patients who underwent valve replacement surgery, and 
groups IIA and B were analysed for patients with NVE. 
-I- Seventy-three percent of patients (19 of 26) in 
group IA and 38$ of patients (3 of 8) in group IB were 
cured of their EE (p=.098) Four of 26 patients (15$) in 
IA died as opposed to 4 of 8 (50$) in IB (p=.066). There 
is a strong trend toward a higher cure and lower mortali¬ 
ty rate after treatment which includes an aminoglycoside, 
although the differences are not significant at the 5$ 
level. One or more major complications occurred in 20 
(77$) of IA patients and 6 (75$) of IB patients. 
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Similarly, larger percentages of patients in IB had em¬ 
bolic episodes, persistent fever on therapy, CHF, and re¬ 
lapse of their disease. None of these differences were 
statistically significant. 
These data were further analysed to determine 
whether any statistically significant differences could 
be demonstrated by grouping various combinations of com¬ 
plications together, thereby creating larger numbers for 
comparison. Each two groups were compared with respect 
to the percentage in each who developed: 
(a) CHF or emboli 
(b) CHF, emboli, or death 
(c) relapse, fever, or death 
(d) death, fever, or CHF 
(e) relapse or death 
(f) death or fever 
(g) relapse, death, or emboli 
Significantly fewer patients in group IA developed com¬ 
plications of death or fever than in group B (p<.05). 
Other analyses showed no significant statistical differ¬ 
ences. However, analysis of these groups after exclusion 
of patients who underwent surgery for their disease de¬ 
monstrates significant differences in outcomes. More pa¬ 
tients were cured with "standard" therapy (13 of 17 or 
76$) than were cured with "alternative" therapy (1 of 6 
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or 17$), p=.0l8. Similarly, fewer patients in the former 
group died than did in the latter group (18$ vs. 67$, 
p=.045). Death or fever occurred significantly more fre¬ 
quently (p=.002) in group IB than in IA once the data was 
controlled for the variable of surgical intervention. 
Other analyses described above did not yield significant 
differences. 
-II- Patients who received less than 4 weeks of am¬ 
inoglycoside therapy (IIB) had a slightly higher rate of 
complications (80$) as compared to patients who who re¬ 
ceived at least 4 weeks of an aminoglycoside (IIA, 75$). 
Similarly, patients in group IIB had slightly higher 
rates of embolic episodes, surgical intervention, and de¬ 
ath. However, a higher percentage of patients in this 
group were cured (8 of 10, 80$ vs. 11 of 16 , 69$) and 
fewer in this group had persistent fever. None of these 
differences were statistically significant (p=.60 to 
.98). The higher percentage of patients with PVE in 
group IIA could negate any benefit associated with longer 
aminoglycoside therapy. But, upon further analysis of 
these 2 groups after exclusion first, of patients with 
PVE, and second, of patients who underwent surgery, no 
significant differences in outcomes could be demonstrated 
between these two groups. 
Among the 10 patients in group IIB, 4 (40$) re- 
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ceived between 12 days and 3 weeks of an aminoglycoside 
(mean = 16 days). Of these patients, 3 (75$) were cured. 
One of those cured also underwent surgery. The remaining 
patient died of an unclear cause following a neurologic 
deterioration attributed to microemboli. 
-Ill- Patients who received the "standard" antibi¬ 
otic therapy alone had lower rates of all major complica¬ 
tions except death as compared to those who underwent 
surgery in addition to "standard therapy". 12 of 18 pa¬ 
tients (67$) in group IIIA and 8 of 8 patients (100$) in 
IIIB had one or more complications (p=.031). The higher 
rate of complications is expected since these complica¬ 
tions are the indications for surgery in IE. Of more im¬ 
portance is the fact that patients who did not receive 
surgery had a higher mortality rate: 3 of 18 (17$) vs. 
1 of 8 (13$). The one patient who died after receiving a 
valve replacement never regained consciousness after a 
valve replacement for persistent bacteremia, and died of 
multi-organ failure. He may have died of causes related 
to his surgery rather than his underlying disease. 
Further comparisons of outcomes between these two groups 
did not demonstrate a significant difference. 
(T) INFLUENCE OF UNDERLYING FACTORS, AGE, 
AND MODE OF PRESENTATION 
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ON OUTCOME IN EE 
Table 20 lists major complications of endocarditis 
and cure rates for patients with various underlying con¬ 
ditions, presenting symptoms, and clinical data which may 
affect the prognosis in this disease. Table 20A shows 
the percentage of all 37 patients with and without a giv¬ 
en clinical feature who develop a given complication. 
Table 20B presents the same information excluding pa¬ 
tients with PVE because the latter have a very poor prog¬ 
nosis as a group. However, there are no major differ¬ 
ences in trends between the tables. Although the numbers 
are small, there does not appear to be any definite 
correlation between underlying conditions (a history of 
CHF, valvular heart disease, or any underlying illness) 
and outcome for these patients. However, a greater per¬ 
centage of patients with a history of CHF died and fewer 
were cured as compared to patients without a history of 
CHF (p>.05). 
Patients over age 60 with non-prosthetic endocar¬ 
ditis had slightly higher rates of complications as well 
as a lower cure rate and a higher death rate than did 
younger patients ( 59$ vs. 100$ and 29$ vs. 0 respec¬ 
tively). The only statistically significant difference 
for the age factor was that patients 60 years or older 
were less likely to have a valve replacement (p=.002). 
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Women were more likely than men to develop complications 
of their disease, including death, whereas men were more 
likely to be cured. Men also had more valve replacement 
operations (p=.3^5 for NVE) 
Fourteen patients (38$) presented with symptoms of 
CHF, but these patients did not develop complications (o- 
verall) more often, although they were more likely to un¬ 
dergo surgery (p=.132 all patients) or to die (p=.125 all 
patients). Although patients with aortic valve infec¬ 
tions have been reported to have a poorer prognosis than 
patients with mitral valve endocarditis, the outcomes of 
these two groups in this study were similar and a trend 
to this effect was not apparent. Patients with a pros¬ 
thetic valve developed complications more frequently than 
patients with NVE (p>.05). Twenty-five percent of pa¬ 
tients with a prosthetic valve as opposed to of pa¬ 
tients without a prosthetic valve had a relapse of EE 
(p=.09). 
Nine of 9 patients who had a vegetation demonstrat¬ 
ed on echocardiogram developed one or more complications 
whereas 12 of 15 patients (80$) without a vegetation on 
echocardiogram developed complications (p=.266). 
Patients with a vegetation were more likely to die 
(p=.533) and to have surgery (p=.00*O. Patients with NVE 
and a vegetation had persistent fevers on therapy signi- 
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ficantly more often (p=.026). This data must be inter¬ 
preted with caution, however, since it may be that echo¬ 
cardiograms were ordered more often for the seriously ill 
patients. 
Patients with disease of duration three months or 
longer at presentation developed complications or re¬ 
quired surgical intervention more frequently but they did 
not have higher death rates than patients with shorter 
durations of illness (Tables 20A and B). None of the 
differences between these two groups were statistically 
significant. 
Table 21 shows the number of patients who developed 
various complications and the mean duration of their ill¬ 
ness from onset of earliest symptoms to diagnosis. 
Patients who required valve replacements had a signifi¬ 
cantly longer duration of illness than those who did not 
undergo surgery (p=.003)• Similarly, patients with vege¬ 
tations demonstrated on echo had a longer duration of 
illness (95 days vs. <47 days, p>.05). Since patients 
with PVE had a significantly shorter duration of illness 
(21 days) than patients with NVE (79 days) despite having 
a poorer prognosis, the data relating to cases of PVE may 
be a confounding variable. Analysis of patients exclud¬ 
ing those with PVE probably allows a more accurate under¬ 
standing (Table 21). Patients with native valve disease 
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who developed complications tended to have disease of 
longer duration at presentation. However, this was not 
true of patients who died of their disease. Of note, the 
one patient who relapsed with NVE had disease of longer 
duration (90 days) than the others who did not relapse 
(78 days). This is in contrast to the shorter duration 
of symptoms noted for patients who relapsed if PVE is in¬ 
cluded. The numbers are small and none of the analyses 
of duration of illness showed significant differences. 
(U) RELAPSE CASES 
Underlying conditions and clinical features of pa¬ 
tients who relapsed were compared with those of patiencs 
who did not relapse (Table 22). Four patients relapsed 
five times. The patient who relapsed twice had strep, 
faecium endocarditis and relapsed after treatment first 
with ampicillin and tobramycin and then after a course of 
penicillin and gentamicin. He was found to have a prob¬ 
able coronary artery embolus on catheterization, but was 
ultimately cured after a third treatment course and a 
valve replacement and a one-vessel CABG. Two of the oth¬ 
er patients received ampicillin and gentamicin (42 days) 
or penicillin and streptomycin (38 days) without evidence 
of complications until they relapsed with EE. The final 
patient had persistent fever during a 17 day treatment 
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course of cephalothin and ampicillin. 
The mean time from termination of therapy to return 
of symptoms was 38 days for the four first relapse epi¬ 
sodes and 29 days for all 5 relapse cases. As demon¬ 
strated in Table 22, there was no significant difference 
between the patients who relapsed and those who did not 
in terms of age, sex, or anatomical site of infection. 
The percentage of patients with prosthetic valves who re¬ 
lapsed (3 of 4, 75?) was twice as large as the percentage 
for those who did not relapse (12 of 33, 36?), although 
this difference was not significant. There were no sig¬ 
nificant differences between the two groups in terms of a 
history of valvular heart disease, a history of CHF, a 
history of other systemic illnesses, or presentation with 
CHF. The percentage of patients who received antibiotic 
treatment for less than 21 days or who received "stan¬ 
dard” therapy for at least 4 weeks did not differ signi¬ 
ficantly between the groups. The median MIC to penicil¬ 
lin was slightly higher for those who relapsed but the 
median MBC to penicillin was slightly lower for those who 
relapsed. 
The outcomes of the patients who relapsed and those 
who did not are compared in Table 23. There were no sig¬ 
nificant differences, although there were only 4 relapse 
episodes with outcome data to compare. The patients who 
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relapsed had slightly higher death and relapse rates (25$ 
and 25 respectively) than patients who did not relapse 
(22$ and 11$ respectively). Similarly, fewer patients 
were cured after relapsing (50$) than after an initial 
episode (67$). The ^ relapse episodes did not have 
higher rates of other complications of endocarditis. 
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DISCUSSION 
The present study analyses our experience with EE 
at the Yale-New Haven medical center. The first part of 
this review presents the clinical features of the 37 pa¬ 
tients who received this diagnosis over a 13 year period. 
The male predominance noted in this patient popula¬ 
tion has been previously reported for IE (99) and for EE 
(44,52,53). The study patients differed from other pa¬ 
tients with IE at these hospitals in that they were all 
Caucasian and did not have a history of intravenous drug 
abuse. 
EE occurs predominantly in older men and in women 
of childbearing age (52). Our data support the finding 
in older men, but does not demonstrate the occurrence of 
EE in young women. The mean age of our patients (60 ye¬ 
ars) was higher than the mean age reported for patients 
with IE (mid to late 40*s) (65). The percentage of pa¬ 
tients over age 60 in this study (51$) contrasts with the 
percentage over age 60 (21$) in a recent review of IE 
(99). 
The major sources of the enterococcal bacteremias 
were genitourinary or gastrointestinal tract disease or 
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manipulation (22 and 24$ respectively) These data support 
other studies (40,52). Open heart surgery has been noted 
to be a potential source of EE (65). In 16$ of the cases 
in this study, cardiac catheterization or surgery was be¬ 
lieved to provide the portal of entry for enterococci. 
Although streptococci usually cause late PVE, 42$ of the 
cases of PVE in this study had early PVE. Watanakunakorn 
(99) has demonstrated an increasing incidence of early 
streptococcal PVE, now second only to Staph. aureus and 
Staph, eoidermidis as an etiologic organism. Dental in¬ 
fections and procedures accounted for 11$ of EE cases, 
confirming previous data (16,25,94). 
The presenting symptoms in these patients occurred 
in frequencies comparable to those reported in other re¬ 
views of IE (13*47,65). The mean duration of symptoms 
prior to diagnosis in the study patients (62 days) is 
consistent with prior reports. Symptomatic periods vary¬ 
ing from 50 days to 108 days have been reported for EE 
(47,65). The mean duration of symptoms in IE prior to 
admission has been decreasing over the years (13). 
The frequencies of the physical findings were simi¬ 
lar to those reported in EE (53) and in IE (47) with the 
exception of fever which was documented in only 76$ of 
patients in this review at Yale. One study of 125 pa¬ 
tients with IE (65) reported a similar percentage (23$) 
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without fever, including 2 of 12 patients (17%) with EE. The 
variable frequencies of this finding may be partially attributed 
to differing study criteria for inclusion of cases. 
The outcomes of patients in this study were examined to 
delineate features affecting prognosis. Sixty-seven percent of 
patients were cured after one treatment course and 72% were cured 
including cases re-treated after relapse. The 33% initial 
treatment failure rate consisted of a 22% mortality rate and 
an 11% relapse rate. The cure rate in patients treated for the 
first time who received combination therapy was 76%. Other reviews 
have reported similar rates of cure (about 80%) with penicillin 
and aminoglycoside therapy for EE (44,53). Another referral 
center recently reported a lower survival rate (57%) for this 
disease (60). 
A number of factors were analysed for their prognostic 
impact on the course of EE. Patients over age 60 had a slightly 
higher rate of complications (including death). Patients with 
any of the following: a history of CHF, CHF on presentation, PVE, 
3 months or more of symptoms before admission, or a vegetation 
detected by ultrasound, tended to fare worse than their counter¬ 
parts with EE. In addition, patients who underwent a second 
treatment course after relapse of their EE had higher death and 
relapse rates and lower cure rates than those treated for their 
first episode of the disease. The de- 
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velopment of CHF, previously identified as a strong negative 
prognostic indicator in BE (17,38,65), was associated with only 
slightly higher rates of certain complications (including death) 
in this study. However, these analyses involved small numbers 
of patients. The predominance of aortic valve and PVE in patients 
who developed CHF confirms the results of other investigators 
(17,38). The majority of our patients died from cardiac causes, 
as in a previous review (77). 
Recent studies have identified the duration of symptoms 
before treatment in non-enterococcal streptococcal endocarditis 
as a feature of prognostic significance (51,66). In tnis review 
of EE, patients with disease of 3 months duration or longer tended 
to have more complications (p>.05). Similarly, patients who 
developed emboli or required surgical intervention had disease of 
longer duration than those without complications. However, even 
after exclusion of patients with PVE, patients who developed 
CHF or died did not have disease of longer duration than those 
without these complications. Thus, the data only partially support 
an association between duration of illness prior to diagnosis 
and the development of major complications. 
Patients with prosthetic valve EE had a significantly 
shorter period of time from onset of symptoms to diagnosis, 
in part because 5 of them had early PVE. In addi- 
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tion, the clinical course of PVE may be accelerated in 
relation to NVE And there is always a stronger suspicion 
of the diagnosis of endocarditis in patients with pros¬ 
thetic valves. 
Three of 4 relapses occurred in association with 
prosthetic valve infections. Asssessment of the rela¬ 
tionship of the duration of illness to the risk of re¬ 
lapse is therefore difficult. The one patient with re¬ 
lapse of NVE had a relatively longer duration of illness. 
Thus, these data can neither support nor challenge a pre¬ 
vious report of non-enterococcal streptococcal endocar¬ 
ditis from this institution which suggested that patients 
with disease of longer duration are at higher risk of re¬ 
lapse and therefore may require more aggressive antibiot¬ 
ic therapy in order to achieve cure. 
The numbers of patients with a given risk factor 
and a given outcome were small. Although some trends 
were apparent, clear associations and statistical signif¬ 
icance were unusual. The strongest prognostic correla¬ 
tions existed between echocardiographically demonstrated 
vegetations and poor outcomes (death, surgery, or persis¬ 
tent fevers). Several features reported to adversely af¬ 
fect outcome in endocarditis (17,18,47) did not demon¬ 
strate clear prognostic significance in this study. 
These factors included a prior history of CHF, valvular 
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heart disease, or any underlying illness, and aortic 
(versus mitral) valve involvement. 
Patients* outcomes were further analysed to assess 
the efficacy of various treatment regimens. There was an 
improvement in the rate of cure from 67$ to 76$ with the 
addition of an aminoglycoside to the antibiotic therapy. 
This improvement was supported by statistically signifi¬ 
cant differences in complication and mortality rates. 
Treatment with or without an aminoglycoside in combina¬ 
tion with a cell wall active agent (penicillin, ampicil- 
lin, or vancomycin) for a minimum of 12 days was the ma¬ 
jor difference between these two groups. However, the 
poorer outcomes in group IB may be partially attributable 
to the shorter total duration of antibiotic therapy in 
this group. 
Despite extensive analysis of treatment groups, no 
significant differences in outcomes were detected between 
patients who received greater than or equal to 4 weeks of 
an aminoglycoside as opposed to less than 4 weeks of an 
aminoglycoside. Of note, even 3 of 4 patients who re¬ 
ceived less than 3 weeks of an aminoglycoside (mean=l6 
days) were cured. 
The literature provides very little data on the is¬ 
sue of duration of aminoglycoside treatment in EE. 
Results favoring a 4 week treatment period in contrast to 
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6 weeks of a combination regimen have been reported re¬ 
cently from several groups (25,80,96). 
The issue of quantifying the duration of aminogly¬ 
coside treatment actually required to optimize outcome 
and minimize aminoglycoside toxicity has not been ad¬ 
dressed in a controlled study. A protracted course of 
aminoglycoside therapy has significant hazards, as seen 
in this study. The results of treatment presented here 
suggest that it may be possible to spare patients expo¬ 
sure to an unnecessarily prolonged course of aminoglyco¬ 
side therapy and thus decrease the treatment-related mor¬ 
bidity. This investigation cannot conclude what might 
actually be the optimal duration. It should be noted 
that although the minimum duration of aminoglycoside 
treatment was 12 days, the minimum duration of total 
treatment was 26 days. It may be possible to abbreviate 
the course of combined therapy and continue a penicillin 
or vancomycin for a total of to 6 weeks and achieve ex¬ 
cellent results. 
The issue of surgical intervention is less contro¬ 
versial. It is very difficult to control for all the 
variables when comparing medical and surgical therapies. 
The patients who received surgery at Yale were seriously 
ill, as evidenced by the very high rates og serious com¬ 
plications. In spite of these complications, they did 
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extremely well, with a 9U cure rate and only one surgery 
related death. The patients who completed a course of 
antibiotic therapy for EE before surgery fared better 
of M patients cured) than those who had earlier surgery 
after a mean of 16 days of therapy (1 death and 6 cures). 
The analysis of treatment groups IIIA and B reveals 
a lower mortality rate among patients who received "stan¬ 
dard" antibiotic therapy and surgery as opposed to those 
who received a "standard" antibiotic regimen alone 
(p>.05). This is in spite of the fact that the surgical¬ 
ly treated patients probably would have failed medical 
treatment. The trend toward improved survival with sur¬ 
gery and antibiotic therapy is supported by several other 
retrospective analyses (17,38). A controlled prospective 
study addressing this issue is needed in order to further 
analyse the variables. 
This retrospective review of cases of EE at Yale 
hospitals has limitations imposed by the size of the 
study. Its retrospective nature requires cautious in¬ 
terpretation of results. Valve replacement surgery in 
combination with antibiotic therapy tended to increase 
the rate of cure in this disease in comparison to out¬ 
comes with antibiotic therapy alone. Patients treated 
with at least 12 days of an aminoglycoside in combination 
with a penicillin or vancomycin had significantly fewer 
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complications and improved survival rates as compared to patients 
who received other antibiotic therapies. In addition, the data suggest 
that patients with EE may achieve equivalent treatment outcomes with 
less than four weeks of aminoglycoside treatment as compared to 4 to 
6 weeks or more of combination therapy. The chi square analyses support 
the lack of association between duration of aminoglycoside therapy 
and outcomes (p=.2 to .99). However, the small number of patients 
available for comparison increases the probability of missing a signi¬ 
ficant association if it does exist (type II error). A well-organised 
prospective controlled study of the treatment of EE would provide the 
best means for further evaluation of the optimal duration of amino¬ 
glycoside therapy in this disease. 
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TABLE 1 
INCIDENCE OF ENDOCARDITIS AT YALE-NEW HAVEN HOSPITAL 
AND ST. RAPHAEL'S HOSPITAL 
YNHH HSR 
Years 1971 -1982 1974-1982 
Number of 
Patients 
Incidence Number of 
Patients* 
Incidence 
TOTAL 138 100% 76 100% 
Streptococcal* 65 47% 32 42% 
Enterococcal 24 17% 6 8% 
Staphylococcal 19 14% 16 21% 
GNR** 14 10% 5 65% 
Otherf 16 12% 17 22% 
* Including enterococci 
** GNR= gram negative rods 
t Other etiologies: fungi, 2-organism endocarditis, unknown, culture 
negative 
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TABLE 2 
RATIO OF MALES TO FEMALES AND SITE OF INFECTION 
IN 37 PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
(INCLUDING 3 PATIENTS FROM THE WEST HAVEN VA HOSPITAL) 
Si te Male Female Male:Female 
Rati o 
Native: AV 11 1 11:1 
MV 3 4 0.75:1 
Both 2 1 2:1 
Prosthetic valve: AV 5 2 2.5:1 
MV 2 2 1:1 
Both 1 0 
Unknown 3 0 
All patients 27 10 2.7:1 
no 
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TABLE 4 
UNDERLYING ILLNESS IN 37 PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
Male Patients Female Patients All Patients 
Valvular: 14* (52) 5 (50) 19 (51) 
RF 2 6 8 (22) 
Prosth. 8 4 12 (32) 
Prior IE 2 0 2 (5) 
H/0 non-specific 6 0 6 (16) 
murmur 
Non-Valvular: 7 (26) 5 (50) 12 (32) 
CHD 1 0 1 
CHF 4 4 8 
CAD 4 2 6 
Other Diseases: 4 (11) 1 (3) 5 (14) 
No Valvular Heart Disease 13 (48) 5 (50) 18 (49) 
No Underlying Illness 10 (37) 1 (10) 11 (30) 
* Number; percent in parentheses. 
LEGEND: 
RF= rheumatic fever or rheumatic heart disease 
CHD= congenital heart disease (ASD and VSD) 
Other Disease= renal failure (2), immunosuppression (2), alcoholic 
liver disease (1), diabetes (2). 
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TABLE 5 
PRIOR SURGERY IN PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
Operation or Procedure 
Cardiac surgery* 
Dental surgery 
Genitorurinary 
TURP 
prostatectomy 
cystoscopy 
vasectomy 
hysterectomy 
Gastrointestinal 
polypectomy 
herniorrhaphy 
TOTAL 
Number of Patients 
6 
6 
5 
1 
1 
1 
1 
1 
2 
1 
1 
18 
*Cardiac valve replacement (4 patients), one 
combined with a CABG; ASD and VSD repair (1 
patient); and catheterization (1 patient). 
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TABLE 6 
PROBABLE SOURCES OF INFECTION IN 37 PATIENTS 
WITH ENTEROCOCCAL ENDOCARDITIS 
Source Number of Patients (%) 
Gastrointestinal 10 (27) 
cancer or polyp 5 
diverticulosis 2 
diverticulitis 1 
surgery 1 
Genitourinary 8 (22) 
urinary tract disease 4 
instrumentation or surgery 4 
No source found 7 (19) 
Cardiac surgery 6 (16) 
Dental work 4 (11) 
Other* 2 (5) 
*Decubitus ulcer, peritoneal dialysis 
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TABLE 7 
PRESENTING SYMPTOMS IN 37 PATIENTS 
WITH ENTEROCOCCAL ENDOCARDITIS 
Symptom(s) Number of Patients Percent 
Fever (>100^) 28 76 
Fatigue, weakness, malaise 26 70 
Chills or sweats 19 51 
Anorexia, weight loss 19 51 
CHF 14 38 
GI symptoms 6 16 
Chest pain 5 14 
Myalgias 5 14 
Cough 4 11 
Back pain 4 11 
Arthralgias 2 5 
Hematuria or dysuria 2 5 
Neurologic (mental status) 2 5 
Headache 2 5 
Skin lesions 2 5 
No symptoms* 2 5 
* Both patients had early PVE 
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TABLE 8 
DURATION OF ILLNESS PRIOR TO THERAPY IN 
37 PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
Valve Number of Patients Duration 
(mean in days ± SE) 
Native 25 (22)* 79 + 11 
Prosthetic** 12 (10) 21 + 5.1 
Aortic 20 (15) 57 ± 13 
Mitral 10 (10) 69 ± 18 
Both 4 (4) 75 + 24 
All patients 37 (32) 62 ± 9.0 
*Number of patients with site of valve involvement; number of 
patients for whom data available in parentheses. 
**Includes 5 cases of early PVE. 
NOTE: Data not available in 5 patients. 3 patients: valve 
site unknown. 
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TABLE 9 
PHYSICAL FINDINGS ON PRESENTATION IN 37 
PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
Sign Number Percent 
Murmur 35 95 
Present, ? duration 15 
New 12 
Old 6 
Change 2 
None 2 
Fever 28 76 
Petechaie 13 35 
Other 10 
Oral 3 
Splinter Hem. 12 32 
Splenomegaly 12 32 
Neuro Findings 7 19 
Osier's Nodes 6 16 
Eye (Roth's, Hemorrhages) 5 14 
Clubbing 4 11 
Janeway's 1 3 
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TABLE 10 
LAB DATA ON PRESENTATION FOR 37 PATIENTS 
WITH ENTEROCOCCAL ENDOCARDITIS 
Test Percent Abnormal 
1. ESR (mean=49) 29/29* 100 
*25: 6 pts. 
26-45: 7 pts. 
46-70: 14 pts. 
>100: 2 pts. 
2. Left shift 30/34 88 
3. Hgb (mean=ll) 31/36 86 
4. Pyuria 19/34 58 
5. Rheumatoid Factor 12/22 55 
6. WBC (mean=9.9) 18/37 49 
<5000: 1 pt. 
5-10,000: 23 pts. 
10-15,000: 14 pts. 
>15,000: 4 pts. 
7. Proteinuria 14/32 44 
1+: 5 pts. 
2+: 7 pts. 
3-4+: 3 pts. 
Neg: 18 pts. 
8. Complement 9/21 43 
CIO: 1/1 
C3: 2/8 
C4: 3/9 
CH50: 3/3 
9. ECHO (vegetation) 10/24 42 
MV=3 
AV=7 
10. Hematuria 12/34 35 
11. Cerebral Spinal 
Fluid 
2/8 25 
normal 6 
Hem. 1 
Infec. 1 
*Number of patients with abnormality (numerator), number 
of patients tested (denominator) 
LEGEND: 1. ESR >15 male, >20 female; 2. >70% polys with 
>5% bands; 3. Anemia: <14 male, <12 female; 4. a3 WBC/HPF; 
5. titer >1:40, where given; 6. WBC >10; 7. ^1+ on 
dipstick; 8. C1Q >150, C3 <78, C4 <14, CH50 <30 (classical) 
or <3 (alternate); 9. echocardiogram report (any time 
during admission) states vegetation seen on valves ; 10. >3 
RBC/HPF; 11. Heme-RBC's (non-traumatic), infected-glu >20 
mg%, prot >45 mg% 
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TABLE 11A 
MI C/MB C* + MEDIANS FOR ORGANISMS 
OF PATIENTS WITHOUT RELAPSE+ 
Organism Pen. Ampi. Genta. Tobra. Strept. Vanco. 
Enterococcus 2.4 
Enterococcus 0.75 50 
Enterococcus 0.5 0.25 4 
Enterococcus 0.5/1 4 
Enterococcus 6.2 0.75 
Enterococcus 3.1 
Enterococcus 2.5/5 25/100 0.19/100 
Enterococcus 0.4/100 12.5/100 250/100 
Enterococcus 1 0.25 
Enterococcus 0.75 3.1 
Enterococcus 3.15/3.15 
Enterococcus 15/15 5/5 1.56/3/12 
Enterococcus 50 1.56/100 0.78/100 
Enterococcus 1.56/100 
Enterococcus 3.1/6.25 
Enterococcus 12.5/25 
Faecal is 4/100 0.5 8.0 1.0 
Faecal is 3.1 
Median MIC 3.1 ± 4.4 .625 ± .7 10.25 ± 7.2 4 137.5 0.89 ± .21 
Median MBC 6.25 ± 19 52.5 + 28 62.5 100 100 ± 24 
*MBC= 100 - indicates that the antibiotic was not bactericidal. 
tData available for 18 of 32 patients. 
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TABLE 11B 
MIC/MBC* + MEDIANS FOR ORGANISMS OF PATIENTS WHO RELAPSEDf 
Organism Pen. Ampi. Genta. Tobra. Strept. Vanco. 
Enterococcus 4/16 62/100 100 
Enterococcus 156/40 
Enterococcus 5/5 
Enterococcus 2.5/6 3.15/6.25 5/10 6.25/100 2/16 
Enterococcus 6.25/100 3.15/6.25 
Faecium 0.5 2 8 32 100 1/16 
Faecium 4 2 2 
Faecium 4/2 2 
Median MIC 
00
 
-H
 2.6 + .3 5 ± 30 47 53 1.5 
Median MBC 5.5 + 24 6.3 ± 1.4 16 ± 9 100 100 16 
* MBC = 100 indicates the antibiotic was not bactericidal 
t Data available for 8 of 10 episodes. 
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TABLE 12 
ANTIBIOTIC TREATMENT REGIMENS FOR 37 PATIENTS WITH ENTEROCOCCAL ENDOCARDITIS 
Total Mean Sum Aminoglycoside 
tint No. Drug Route Dose Days Days Dose Treatment Days 
1 Vancomycin IV 2 10 10 2 A= 18 
Gentamicin IV 150 2 B= 10 
i allergy 120 5 29 
105 3 
100 3 T=29 
50 16 29 80 
Penicillin IV 12 2 
15 4 
20.4 12 18 18 
2 Penici11 in IV 20 15 15 20 
Streptomycin IM 1 3 3 1 A=46 46 
Gentamicin IV 180 7 38 217 T=46 
225 31 
Ampicillin IV 9 31 31 9 
3 Keflin IV 4 17 17 4 T= 17 0 
i allergy 
4 Ampicillin IV 8 36 36 8 
Gentamicin IV 60 3 3 60 A=36 36 
Streptomycin IM .25 12 12 .25 
Tobramycin IV 80 9 
130 2 T=37 
100 10 21 94 
5 Ampicillin IV 12 46 46 * 12 A=46 46 
Tobramyci n IV 270 46 46 270 
6 Penicillin IV 21 
20 
24 21 41 23 A=41 41 bse Gentamicin IV 180 20 
210 21 41 195 T=41 
7 Penicillin IV 30 12 A=50 
18 38 50 21 T= 5 7 57 )se Gentamicin IV 180 7 14 160 
140 7 
Streptomycin IM 1 43 43 1 
8 Ampicillin IV 6 10 
18 11 
12 6 27 12 
Gentamicin IV 65 4 
100 4 31 
240 5 
300 2 1 120 4 19 155 
Cefoxitin IV 9 8 
j 4 5 13 7 
Tobramycin IV 60 7 
40 5 12 52 
Carbenicillin IV 6 6 6 6 A=24 
Vancomycin IV .600 3 D=7 
. inn 4 7 .43 1530 

; 12 - CONTINUED 
122 
;nt No. Druq Route Dose Days 
Ampicillin IV 9 26 
Gentamicin IV 140 13 
Tobramycin IV 23 22 
Penicillin IV 18 8 
) Vancornycin IV 2 35 
allergy 1 3 
Gentamicin IV 240 18 
Ampici11 in IV 8 13 
1 9 10 
1 Gentamicin IV 240 25 
Vancomycin IV 2 16 
Penici11 in IV 24 16 
2 Gentamicin IV 240 3 
120 10 
80 3 
3 Cefamandole IV 6 3 
\\ Penici11 in IV 20 42 
Streptomycin IM 1 14 
3 Ampicillin IV 9 42 
Gentamicin IV 180 4 
120 7 
100 15 
67 16 
5 Ampici11 in IV 6 16 
apse Gentamicin IV 210 9 
180 16 
160 17 
Penicillin IV 18 26 
1 Penici11 in 
IV 21 23 
12 19 
Gentamicin IV 120 7 
75 6 
Streptomycin IM 0.5 7 
0.25 18 
8 Ampici11 in IV 0.4 17 
Gentamicin IV 24 25 
Amoxici11 in P0 190 5 
Gentamicin IM 24 4 
9 Penici11 in IV 21 28 
Gentamicin IV 120 4 
150 10 
105 5 
53 9 
Total Mean Sum Aminoglycoside 
Days Dose Treatment Days 
26 9 
13 140 A=35 35 
22 23 
8 18 T=35 
B=18 
38 1.9 D=38 20 
18 240 T=36 
A=13 
23 8 B= 12 
25 240 C=23 25 
16 2 T=36 
16 24 A= 16 
16 
16 135 T= 16 
3 6 T=3 0 
42 20 A=14 14 
14 1 T=42 
42 9 
A=42 
T=42 42 
42 98 
16 6 A=42 42 
T=42 
42 178.3 
26 18 
42 16.9 A= 37 
13 99.2 T=42 38 
25 0.32 
17 0.4 A=26 
25 24 31 
5 190 T=28 
4 24 
28 21 
A=28 
T=28 
28 107 
28 
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;nt No. Drug Route Dose Days 
Total 
Days 
Mean 
Dose 
Sum 
Treatment 
Aminoglycoside 
Days 
) Penici11in IV 18 10 10 18 
Gentamicin IV 180 52 A=52 
150 2 54 179 T=52 54 
Ampicillin IV 12 42 42 12 
No Treatment 0 
Ampicillin IV 12 42 42 12 A=42 
Gentamicin IV 300 22 22 300 T=42 42 
Tobramycin IV 210 20 20 210 
Penici11 in IV 9 6 
3 21 13 A= 12 
10 4 
2.5 10 33 19 T=34 12 
Streptomycin IM 1 12 12 1 
1 Ampici11 in IV 12 7 
6 4 A=26 
9 23 34 9 
Gentamicin IV 360 21 T=38 38 
200 17 38 236 
Penicillin IV 20 4 4 20 
5 Penici11 in IV 16 40 40 16 A=40 
Gentamicin IV 210 21 40 
140 19 40 177 T=40 
5 Kefl in IV 12 6 6 12 
Streptomycin IM 2 5 5 2 5 
Penici11in IV 4 13 13 4 T=19 
1 Gentamicin IV 230 2 C=8 
140 10 12 155 T=20 12 
Ampici11 in IV 8 8 8 8 
8 Penici11 in IV 20 42 42 20 A=38 
Streptomycin IM 1 11 38 
0.5 27 38 0.64 T=42 
9 Penicillin IV 40 41 41 40 A=41 
apse Streptomycin 
IM 1 15 15 1 T=41 
Gentamicin IM 210 26 26 210 41 
0 Penici11in IV 20 42 42 20 A=42 
Tobramycin IV 210 42 42 210 T=42 42 
1 Kefl in IV 8 18 18 8 
allergy Streptomycin 
IM 2 
1 
6 
2 T=18 15 
0.5 7 15 1.2 
2 Vancomycin IV 2 42 42 2 D=42 0 
allergy T=42 
I 
E 12 -CONTINUED 
ent No. Drug Route Dose Days 
3 Penicillin IV 20 26 
Streptomycin IM 1 18 
4 Kanamycin IM 1 4 
Kefl in IV 8 4 
Penicillin IV 24 7 
48 36 
Streptomycin IM 2 10 
1 33 
5 Penicil1 in IV 20 46 
Streptomycin IM 1 33 
6 Keflin IV 9 
Ampici11in IV 8 
7 AmDici11in IV 6 35 
apse 
Streptomycin IM 
12 
2 
3 
3 
1 17 
8 Erythromycin IV 6 8 
allergy Erythromyci n PO 6 38 
9 Penicillin IV 20 26 
Streptomycin IM 2 6 
1 26 
0 Ampicillin IV 6 10 
Vancomycin IV 0.3 3 
C.5 14 
0.25 5 
1 Penici11in IV 25 10 
30 20 
20 2 
Streptomycin IM 1 14 
2 2 
Gentamicin IM 180 9 
2 Ampicillin IV 8 42 
Gentamicin IM 240 26 
120 3 
Total Mean Sum Aminoglycoside 
Days Dose Treatment Days 
26 20 A= 18 
18 1 T=26 18 
4 1 
4 8 A=43 
47 
43 44.1 T=47 
43 1.2 
46 20 A=33 
33 1 T=46 33 
9 C=8 
8 T=17 0 
A=20 
38 6.5 C=38 
20 1.2 T=38 20 
8 6 
38 6 T=46 0 
26 20 A=26 
T=26 26 
26 1.2 
10 6 C=10 
D=22 
T=32 
22 0.4 
A=25 
0 
32 27.8 T= 32 
25 
16 1.1 
9 180 
42 8 A=29 
C=42 
29 229 T=42 29 
Total days of a penicillin plus an aminoglycoside 
Total days of vancomycin plus an aminoglycoside 
Total days of ampicillin 
Total days of vancomycin without an aminoglycoside 
Total days of antibiotic treatment 
/ 
TABLE 13 
CRITERIA FOR ASSIGNMENT OF PATIENTS 
INTO TREATMENT GROUPS 
GROUP 
IA Standard Antibiotic Therapy"* 
2 
IB Alternative Antibiotic Therapy 
11A ^ 4 weeks aminoglycoside therapy 
I IB < 4 weeks aminoglycoside therapy 
111A Antibiotic therapy alone 
111B Antibiotic + surgical therapy 
Defined as: Penicillin, ampicillin, or 
vancomycin in combination with an 
aminoglycoside. 
2 
Defined as: Single agent therapy or any 
combination therapy except that of a 
cell wall active agent plus an amino- 
glycoside. 
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TABLE 14 
COMPLICATIONS OF TREATMENT 
Max. Creat. 
No. of patients 
1-2 2-3 3-4 >4 
Duration of renal dysfunction 
unknown or 
till death 
1-3 wk 3-6 wk chronic 
ami c i n 
atomyc i n 
amycin 
ami ci n/ 
comycin 
ami ci n/ 
ramycin 
ami ci n/ 
jptomycin 
7/23* (30%) 2 5 
2/16 (13%) 
1/8 (13%) 
1/2 (50%) 
2/7 (29%) 1 
1/6 (17%) 1 
3 
2 1 
1 
1 
1 1 
nber of patients with complications over total number treated. 
1 
1 
1 
1ENAL: 
Fever Mi set 
Ampici11 in-2 (13%) 3 
Penici11in-6 
Vancomycin/Gentamicin-1 
istib./Hearing Rash 
)tomycin-5 (31%)* Ampicillin-4 (25%) 
Eosinophilia 
5 
nber of patients (percent of those receiving that drug) 
lebitis, leukopenia 
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TABLE 16 
COMPARISON OF OUTCOME*: NATIVE VALVE ENDOCARDITIS (NVE) 
VS. PROSTHETIC VALVE ENDOCARDITIS (PVE) 
NVE (N=25)f PVE (N=ll)f Early PVE (N=5)t 
Number of Patients (%) Number of Patients (%) Number of Patients (%) 
Cure 19 (76) 5 (45) 2 (40) 
Any comp. 20 (80) 9 (82) 4 (80) 
Embol i 12 (48) 6 (55) 3 (60) 
CHF 7 (28) 3 (27) 2 (40) 
Relapse 1 (4) 3 (27) 1 (20) 
Surgery 10 (40)** 0** 0 
Death 5 (20) 3 (27) 2 (40) 
* Relapse episodes exc' uded 
+ Number of patients 
* p= .016 ; al1 other p values >.05 
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TABLE 17 
AGE DISTRIBUTION AND AGE-RELATED MORTALITY 
RATES OF ENTEROCOCCAL ENDOCARDITIS CASES 
Fatalities 
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TABLE 18A 
COMPARISON OF TREATMENT GROUPS I 
Number 
Mean age (years) 
>60 years old 
Mitral valve 
Aortic valve 
Prosthetic valve 
History of valv. HD 
History of CHF 
History of other dis. 
Present with CHF 
Mean (days) 
duration of symptoms 
Duration a3 months 
Duration-treatment 
<21 days 
Valve replacement 
•p<0.05 
A B 
26 8 
58 61 
12 (46%) 4 (50%) 
6 (23%) 1 (13%) 
14 (54%) 4 (50%) 
8 (31%) 3 (38%) 
13 (50%) 4 (44%) 
3 (12%) 3 (38%) 
3 (12%) 1 (13%) 
8 (31%) 4 (50%) 
71 43 
9 (35%) 1 (13%) 
4 (16%)* 7 (88%) 
8 (31%) 2 (25%) 
130 

TABLE 18B 
COMPARISON OF TREATMENT GROUPS II 
Number 
Age (years) 
*60 year old 
Mitral valve 
Aortic valve 
Prosthetic valve 
History of valv. HD+ 
History of CHF 
History of other dis. 
CHF symptoms 
Mean duration of 
symptoms (days) 
Duration *3 months 
Valve replacement 
DRUGS: 
Ampici11 in 
Penici11 in 
Vancomycin 
CWA combination** 
Gentamicin 
A B 
16 10 
59 50 
9 (56%) 4 (40%) 
6 (38%) 2 (20%) 
8 (50%) 6 (60%) 
8 (50%)* 0* 
11 (69%) 2 (20%) 
1 (6%) 2 (20%) 
1 (6%) 2 (20%) 
5 (31%) 3 (30%) 
59 93 
5 (31%) 4 (40%) 
4 (25%) 4 (40%) 
4 (25%) 2 (20%) 
8 (50%) 5 (50%) 
0 1 (10%) 
4 (25%) 2 (20%) 
7 (44%) 4 (40%) 
3 (19%) 4 (40%) 
2 (13%) 0 
Streptomycin 
Tobramycin 
*p < 0.05 
T valvular heart disease 
**Combination of cell wall active agents 
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TABLE 18C 
COMPARISON OF TREATMENT GROUPS III 
A B 
Number 18 8 
Age (years) 60 55 
*60 years old 10 (56%) 3 (38%) 
Mitral valve 7 (39%) 1 (13%) 
Aortic valve 9 (50%) 5 (63%) 
Prosthetic valve 8 (44%)* 0* 
History of VHD+ 11 (61%) 2 (25%) 
History of CHF 3 (17%) 0 
History of other dis. 1 (6%) 2 (25%) 
CHF symptoms 4 (22%) 4 (50%) 
Mean duration of 
symptoms (days) 
51* 115* 
Duration ^3 months 4 (22%) 5 (63%) 
Duration of antibiotic 
treatment <21 days 3 (17%) 1 (13%) 
* p <.05 
t History of valvular heart disease 
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TABLE 19A 
COMPARISON OF OUTCOME IN PATIENTS RECEIVING 
STANDARD VERSUS ALTERNATIVE THERAPY 
Number of 
Cure* 
Any 
Emboli Fever CHF Relapse Death 
Patients Comp. 
1 
A 26 19 (73) 20 (77) 11 (42) 6 (23) 6 (23) 3 (12) 4 (15) 
B 8 3 (38) 6 (75) 4 (50) 4 (50) 3 (38) 1 (13) 4 (50) 
TALS 34 22 (65) 27 (79) 15 (44) 10 (29) 9 (26) 4 (12) 8 (24) 
A= standard therapy *) 
all patients 
B= alternative therapy j 
Number of Any 
Patients 
Cure* _—V 
Comp. 
Emboli Fever CHF Relapse Death 
C 17 13 (76) 10 (59) 7 (41) 3 (18) 4 (24) 3 (18) 3 (18) 
D 6 1 07) 6 (100) 4 (67) 4 (67) 3 (50) 1 (17) 4 (67) 
3TALS 23 14 (60) 17 (74) 11 (48) 7 (30) 7 (30) 4 (17) 7 (30) 
C= standard therapy 
D= alternative therapy 
patients with surgery excluded 
Number of patients; percent in parentheses. 
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TABLE 19B 
COMPARISON OF OUTCOME IN PATIENTS RECEIVING GREATER THAN 
OR LESS THAN 4 WEEKS OF AN AMINOGLYCOSIDE 
Number of 
Patients 
Cure* Any 
Comp. 
Emboli Fever CHF Relapse Death 
A 16 11 (69) 12 (75) 6 (38) 4 (25) 5 (31) 3 (19) 2 (13) 
B 10 8 (80) 8 (80) 5 (50) 2 (20) 1 (10) 0 2 (20) 
OTALS 26 19 (73) 20 (77) 11 (42) 6 (23) 6 (23) 3 02) 4 (15) 
A: ^4 weeks aminoglycoside therapy ( all patients 
B: <4 weeks (>12 day) aminoglycoside treatment J 
Number of 
Patients 
Cure* Any 
Comp. 
Emboli Fever CHF Relapse Death 
C 8 4 (50) 6 (75) 3 (38) 3 (38) 3 (38) 1 (13) 1 03) 
D 10 8 (80) 6 (60) 5 (50) 2 (20) 1 (10) 0 2 (20) 
rOTALS 18 12 (67) 12 (67) 8 (44) 5 (28) 4 (22) 1 (6) 3 (17) 
C: *4 weeks mi noglycoside therapy 1 NVE 
D: <4 weeks aminoglycoside J 
Number of 
Patients 
Cure* 
Any 
Comp. 
Emboli Fever CHF Relapse Death 
E 12 7 (58) 8 (67) 4 (33) 2 07) 2 (17) 3 (25) 2 (17) 
F 6 5 (83) 4 (67) 3 (50) 1 07) 0 0 1 (17) 
TOTALS 18 12 (67) 12 (67) 7 (39) 3 (17) 2 (11) 3 (17) 3 (17) 
E: *4 weeks 
F: <4 weeks 
aminoglycoside pat1ents w1th 
aminoglycoside 
surgery excluded 
'Number of patients; percent in parentheses. 
\ 
TABLE 19C 
COMPARISON OF OUTCOME IN PATIENTS WHO RECEIVED ANTIBIOTIC 
THERAPY ALONE VS. ANTIBIOTIC THERAPY AND SURGERY 
I 
1 Number of Patients Cure* Any Comp. Emboli Fever CHF Relapse 
A 18 12 (67) 12 (67) 7 (39) 3 (17) 2 (11) 3 (17) 
B 8 7 (88) 8 (100) 4 (50) 3 (38) 4 (50) 0 
1TALS 26 19 (73) 20 (77) 11 (42) 6 (23) 6 (23) 3 (12) 
A: antibiotic treatment alone ("standard treatment") 
B: antibiotic treatment plus surgery ("standard treatment") 
Number of patients; percent in parentheses. 
ii 
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Death 
3 (17) 
1 (13) 
4 (15) 
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TABLE 21 
RELATIONSHIP OF DURATION OF ILLNESS TO SPECIFIC COMPLICATIONS 
All Patients (N=37) Mean Duration=62 days 
No. Comp. CHF Surgery Emboli Relapse Veget,t Death 
N* 7(5) 10 10 (9) 19 (18) 4 9 (8) 8 (6) 
Duration 60 
(mean in days) 
57 101 63 38 95 47 
± SE 17 16 18 13 17 22 22 
P value >.05 >.05 .003 >.05 >.05 >.05 >.05 
NVE Patients (N=25) Mean Duration= 79 days** 
No. Comp. CHF Surgery Emboli Relapse Veget.+ Death 
N* 5 7 10 (9) 12 1 8 (7) 5 (4) 
Duration 53 
(mean in days) 78 101 84 90 105 66 
± SE 14 18 19 17 -- 23 29 
P value++ >.05 >.05 >.05 >.05 -- >.05 >.05 
PVE Patients (N=12) Mean Duration= 
*** 
21 days 
No. Comp. CHF Surgery Emboli Relapse Veget.t Death 
N* 2 (1) 3 0 7 (6) 3 1 3 (2) 
Duration 23 
(mean in days) 9.0 
— 22 20 30 11 
± SE 3 — 8 5 — -- 
P value +t .031 >0.05 >0.05 -- -- 
* Total number of patients; number with data available, if different. is in 
parentheses. 
t Vegetation seen on echocardiogram. 24 patients had echocardiograms. 
** NVE=Native valve endocarditis 
tt T test of patients with that complication vs. those without that complication. 
***PVE=Prosthetic valve endocarditis 
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TABLE 22 
COMPARISON OF PATIENTS WHO RELAPSED 
WITH NON-RELAPSE PATIENTS 
Relapse Non-Relapse 
Number 4 33 
Mean age (years) 61 62 
Age >60 2 (50) 17 (51) 
MV 2 (50) 8 (24) 
AV 2 (50) 18 (55) 
Both 0 4 (12) 
PVE 3 (75) 12 (36) 
History of valvular HD 3 (75) 14 (42) 
History of CHF 0 8 (24) 
History of other 0 5 (15) 
CHF symptoms 0 14 (42) 
Duration of symptoms 38 days 63 days 
Duration *3 months 1 (25) 9 (27) 
Treatment s 21 days 1 (25) 7 (21) 
Standard ^4 weeks* 3 (75) 13 (39) 
M: F 3:1 2.7:1 
Median MIC pen. 4.0 3.1 
MBC pen. 4.5 5.5 
*"standard" combination therapy: *4 weeks 
NOTE: p >.05 for all comparisons 
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TABLE 23 
COMPARISON OF OUTCOME IN ENTEROCOCCAL ENDOCARDITIS: 
FIRST EPISODES VS. RELAPSE EPISODES 
Relapse Episodes* * First Episodes+ 
Cure 2 (50%) 24 (67%) 
Any Comp. 3 (75%) 29 (81%) 
Emboli 1 (25%) 18 (50%) 
Surgery 1 (25%) 10 (28%) 
Fever 0 10 (28%) 
Mortality 1 (25%) 8 (22%) 
Relapse 1 (25%) 4 (11%) 
NOTE: p >.05 for all comparisons 
* 4 patients 
t 36 patients 
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